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1. Introduction 
Since 2000, 13 External Quality Assurance System (EQAS) reports have been issued with this 
report being the 14th. The WHO Global Foodborne Infections Network (WHO GFN) focuses on 
enhancing World Health Organization (WHO) Member States’ capacity to detect and respond to 
foodborne disease outbreaks by conducting laboratory-based surveillance of Salmonella and other 
foodborne pathogens. Since its inception, the scope of WHO GFN has expanded to include 
additional foodborne pathogens like Shigella and Campylobacter. Salmonella, Campylobacter and 
Shigella are among the most important foodborne pathogens worldwide and account for millions of 
cases of diarrheal disease and thousands of deaths per year, impacting both developing and 
industrialized countries. Furthermore, the increased number of Salmonella and Shigella isolates 
which are resistant to antimicrobials is of major concern since these isolates are associated with 
infections characterized by increased morbidity and mortality. 
The EQAS is organized annually by the Technical University of Denmark, National Food Institute 
(DTU Food), Kgs. Lyngby, Denmark in collaboration with Centers for Disease Control and 
Prevention (CDC) in Atlanta, USA; World Health Organization (WHO) in Geneva, Switzerland; 
Public Health Agency of Canada (PHAC) in Canada; National Salmonella and Shigella Center 
(NSSC), National Institute of Health, Department of Medical Science in Thailand and Institute 
Pasteur (IP) in Paris, France.  
Individual laboratory data are confidential and only known by the participating laboratory, the 
EQAS Organizer (DTU Food) and possibly the respective WHO GFN regional centre. All summary 
conclusions are made public. The goal set by WHO GFN aims towards having all national reference 
laboratories perform Salmonella serotyping with a maximum of one deviation out of eight strains 
tested (error rate of 13%) and performing antimicrobial susceptibility testing (AST) of Salmonella 
and Shigella with a maximum error rate of 10% (either <5% very major / major errors and <5% 
minor errors, or <10% minor errors). Minor deviations are defined as classification of an 
intermediate strain as susceptible, resistant or vice versa (i.e. I ↔ S or I ↔R). Major deviation is 
the classification of a susceptible strain as resistant (i.e. S → R). Very major deviation is the 
classification of a resistant strain as susceptible (i.e. R → S). In this report, the deviations of AST 
results are divided into two categories, i.e. critical deviations which include major and very major 
deviations, and total deviations which include also the minor deviations. No quality threshold has 
been determined in relation to identification of Campylobacter ssp., serotyping of Shigella, or 
identification of the unknown foodborne pathogen. 
In EQAS 2014, the regions were redefined for all countries worldwide. This lead to some 
reorganization of countries into new regions compared to previous years, why interpreting region 
based results from 2014 and forward with results before 2014 should be done with care. The 
countries belonging to each region is listed in Appendix 1.  
Appendices 2-5 present additional background information in relation to the WHO EQAS 2014. 
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2. Summary 
The summary report is divided into five sections; the Salmonella components, the Shigella 
components, reporting of ESBL Salmonella and Shigella, the Campylobacter components, and 
identification of the unknown strain. All results reported in the summary can be found in Appendix 
1. 
Salmonella EQAS components 
The acceptance threshold for the EQAS Salmonella serotyping component was met by 68% (n = 
102) of the 149 participating laboratories. In addition, 57% (n = 85) of the laboratories tested all 
eight strains with a total at 92% (n = 969) of all tests being correct, representing an increase 
compared to 2013. The ability to correctly serotype the internal control strain increased to the 
highest level at 98%, previously only observed in 2011. 
On a region-based categorization of participating laboratories, the Caribbean, Central Asia & 
Middle East, Africa and Latin America all correctly serotyped between 60% and 90% of the test 
strains, where as China, Russia, Southeast Asia and Europe correctly serotyped between 90 and 
99% of the test strains. North America and Oceania both serotyped all eight strains 100% correctly.  
The main problem regarding the Salmonella serotyping appeared to be with WHO S-14.1 
(Orion/Orion var. 15; 3,15:y:1,5), WHO S-14.4 (Napoli; 9,12:l,z13:e,n,x), and WHO S-14.5 (Ohio; 
6,7:b:l,w), with 10%, 17% and 14% deviation, respectively. 
Concerning the Salmonella AST component for the EQAS 2014, the performance recorded was 
maintained on a similar level as in the EQAS 2013, with low deviations of 3% minor, 1% major, 
and 1% very major deviations. Deviations categorized by the tested antimicrobials revealed that CIP 
caused the difficulties of the observed deviations (19%) most likely due to the often observed 
double zone when performing disk diffusion.  
For the 155 laboratories performing the Salmonella AST component, only 74% (115 laboratories) 
reported data for AST of the control strain E. coli ATCC 25922. This is an alerting decrease, and it 
is of extreme importance to once again emphasize that this component represents the true indicator 
for the laboratory as to the performance of AST.  
Shigella EQAS components 
The Shigella components included in the EQAS consist of serogrouping (i.e. the identification of 
the species), serotyping (i.e. the further typing of the species), and AST. 
For the Shigella serogrouping component in EQAS 2014, the deviations observed ranged from 
2.4% to 5.6%, for the four Shigella strains. This is an increase compared to the very low level of 
deviations observed in EQAS 2013, with a maximum of 0.9%.  
The serotyping component was performed by a total of 83 laboratories for the two strains WHO 
2014 SH-14.3 (S. flexneri; 2/2b) and WHO 2014 SH-14.4 (S. boydii; 2), with deviating results 
observed at 16.3% and 7.2%, respectively. The serotyping component was not required for the S. 
sonnei serogroup (WHO 2014 SH-14.1 and WHO 2014 SH-14.2). According to the geographical 
distribution of the participating laboratories, this year Caribbean was again represented. However, 
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the one laboratory representing the region did not manage to correctly serotype the one strain that 
they tested. The remaining results, on a region-based categorization, ranged from 58.3% (Africa) to 
100% correctly serotyped strains. 
For the results of the Shigella AST component, the number of participating laboratories increased to 
the levels before the EQAS 2013, with 116 participating laboratories in EQAS 2014. The results 
obtained were in 92% of the cases in agreement with the expected results and consistent with 
previous years. Minor, major and very major deviations were observed in 4%, 1%, and 3% of the 
reported results, respectively. Categorizing the tested antimicrobials according to the deviations 
revealed that CIP (34.2%) and CAZ (14.1%) caused difficulties in the AST component. 
A region-based categorization of the results revealed correct test results between 76.5% (Caribbean) 
and 98.4% (Russia), with a very high level of critical deviations observed in Caribbean (18.4%), 
with the remaining regions all below 10%.  
ESBL EQAS component 
A part of the EQAS is to detect and confirm ESBL production in the Salmonella and Shigella 
strains. If participating in this component of the EQAS, all strains showing reduced susceptibility to 
cefotaxime (CTX), ceftazidime (CAZ) and/or ceftriaxone (CRO) should be tested for ESBL 
production. 
For the EQAS 2014, one Salmonella ESBL-producer (WHO 2014 S-14.7) and two Shigella ESBL-
producers (WHO 2014 SH-14.1 and WHO 2014 SH-14.2) were included. For the Salmonella strain, 
the gene accounting for the phenotype was CTX-M-3, and the two confirmatory tests (CAZ/Cl:CAZ 
and CTX/Cl:CTX) showed 11% and 13% of deviations in reporting correct results, respectively. 
For the Shigella strain WHO 2014 SH-14.1 (CTX-M-15), deviations of the confirmatory test results 
were observed to 9% and 8%, respectively. For the WHO 2014 SH-14.2 (CTX-M-15), the deviating 
results were observed to 12% and 8%, respectively.  
Campylobacter EQAS components 
Interpretation of the results for Campylobacter in EQAS 2014 only included WHO 2014 C-14.2 due 
to the fact that the produced lyophilized WHO 2014 C-14.1 proved to be contaminated and 
therefore could not be distributed.    
A total of 101 laboratories participated in the identification of the C. coli WHO 2014 C-14.2 strain 
with a result of 85% correct species identification. On a region-based characterization, the accuracy 
in Campylobacter identification ranged from 57% (Central Asia & Middle East) to 100% 
(Caribbean, North America, Oceania, and Russian regions). 
Concerning the Campylobacter AST component in the EQAS 2014, 50 laboratories participated. 
The overall performance of the AST showed 1.6% major deviations, and 7.2% very major 
deviations, giving a total of 8.8% critical deviations, the highest level observed in the history of this 
WHO EQAS.  
From the categorization of the antimicrobials, the results showed no problems when testing ERY 
and GEN. However, NAL, STR, and TET all showed deviations above 10% (11.9%, 16.7%, and 
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11.1%, respectively). On a region-based characterization, the performance in Africa is noteworthy, 
with a deviation level of 48.5% critical deviations, whereas Central Asia & Middle East, China, 
Caribbean, North America, and Latin America all perfectly performed the test without deviations. 
Europe and Southeast Asia reported deviations at 2.6% and 12.5%, respectively. In EQAS 2014 no 
laboratories in the Oceania or Russian regions participated in the Campylobacter AST component.  
For the QC strain Campylobacter jejuni ATCC 33560 only 32 laboratories reported AST. Again, 
we have to emphasize the importance of including this component as it represents the true indicator 
for the laboratory’s performance of AST. In EQAS 2014, the antimicrobials causing most problems 
were GEN and ERY, however the percentage of laboratories reporting correct AST results for these 
two compounds increased to 90% and 84% (compared to 82% and 83% in EQAS 2013), 
respectively. 
Identification of unknown culture EQAS component 
For this part of the EQAS, an unknown culture is provided for identification. In EQAS 2014, the 
unknown strain was the Gram negative Yersinia pseudotuberculosis. 
A total of 122 laboratories participated in this component, with 74% identifying the strain correctly. 
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Figure 1. Countries participating* in the WHO EQAS 2014 
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List of Countries in the 10 Regions 
 
Africa 
Algeria Gabon Reunion 
Angola Gambia Rwanda 
Benin Ghana Saint Helena 
Botswana Guinea Sao Tome and Principe 
Burkina Faso Guinea-Bissau Senegal 
Burundi Kenya Seychelles 
Cameroon Lesotho Sierra Leone 
Cameroun Liberia Somalia 
Cape Verde Libyan Arab Jamahiriya South Africa 
Central African Republic Madagascar South Sudan 
Chad Malawi Sudan 
Comoros Mali Swaziland 
Congo (Brazzaville) Mauritania Tanzania, United Republic of 
Congo, Democratic Republic of the Mauritius Togo 
Cote d'Ivoire (Ivory Coast) Mayotte Tunisia 
Djibouti Morroco Uganda 
Egypt Mozambique Western Sahara 
Equatorial Guinea Namibia Zambia 
Eritrea Niger Zimbabwe 
Ethiopia Nigeria  
 
Caribbean 
Anguilla Dominica Saint Martin 
Antigua and Barbuda Dominican Republic Saint Vincent and the Grenadines 
Aruba Grenada Saint-Barthélemy 
Bahamas Guadeloupe Sint Maarten 
Barbados Haiti St. Kitts and Nevis 
Bonaire, Saint Eustatius and Saba Jamaica Trinidad and Tobago 
British Virgin Islands Martinique Turks and Caicos Islands 
Cayman Islands Monserrat Virgin Islands (US) 
Cuba Puerto Rico  
Curaçao Saint Lucia  
 
Central Asia & Middle East 
Afganistan Israel Pakistan 
Armenia Jordan Palestine 
Azerbaijan Kazakhstan Qatar 
Bahrain Kuwait Saudi Arabia 
Bangladesh Kyrgyzstan Syria 
Bhutan Lebanon Tajikistan 
Georgia Macao Timor Leste (West) 
Hong Kong Maldives Turkmenistan 
India Mongolia United Arab Emirates 
Indonesia Myanmar (ex-Burma) Uzbekistan 
Iran, Islamic rep. Of Nepal Yemen 
Iraq Oman  
 
China 
China 
 
Europe 
Albania Guerney and Alderney Norway 
Andorra Hungary Poland 
Austria Iceland Portugal 
Appendix 1 – Figure and Tables, page 3 of 37 
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Belarus Ireland Romania 
Belgium Italy San Marino 
Bosnia Jersey Serbia 
Bulgaria Kosova Slovak Republic 
Croatia Kosovo Slovakia 
Cyprus Latvia Slovenia 
Czech Republic Liechtenstein Spain 
Denmark Lithuania Svalbard and Jan Mayen Islands 
Estonia Luxembourg Sweden 
European Union Macedonia Switzerland 
Faroe Islands Malta Turkey 
Finland Man, Island of Ukraine 
France Moldova United Kingdom 
Germany Monaco Vatican City State (Holy See) 
Gibraltar Montenegro  
Greece Netherlands  
 
Latin America 
Argentina El Salvador Nicaragua 
Bolivia Falkland Islands (Malvinas) Panama 
Brazil French Guiana Paraguay 
Chile Guatemala Peru 
Colombia Guyana Suriname 
Costa Rica Honduras Uruguay 
Ecuador Mexico Venezuela 
 
North America 
Bermuda Greenland United States of America 
Canada Saint Pierre and Miquelon  
 
Oceania 
Australia Papua New Guinea Guam 
Kiribati Tonga New Caledonia 
New Zealand French Polynesia Samoa, American 
Solomon, Islands Micronesia Vanuatu 
Fiji Samoa  
Marshall Islands Tuvalu  
 
Russia 
Russia  
 
Southeast Asia 
Brunei Darussalam Lao PDR Taiwan 
Cambodia Malaysia Thailand 
Japan Philippines Viet Nam 
Korea, North Singapore  
Korea, Rep of Sri Lanka  
 
  
Appendix 1 – Figure and Tables, page 4 of 37 
 
 
 4 
Table 1. EQAS participating laboratories’ performance of Salmonella serotyping  
 
EQAS 
iteration 
 
Labs serotyping all 
provided strains Correct test results 
No. % No. % 
2000 34 92 165 76 
2001 79 82 513 72 
2002 80 81 668 91 
2003 69 54 692 80 
2004 78 61 701 81 
2006 105 81 808 85 
2007 109 78 920 88 
2008 100 66 888 83 
2009 119 83 974 86 
2010 129 87 998 89 
2011 109 89 878 92 
2012 122 81 936 83 
2013 74 59 812 89 
2014 85 57 969 92 
Average 97 75 780 85 
 
Table 2. Ability of EQAS participating laboratories to serotype the test Salmonella strains  
 
Number 
of strains 
correctly 
serotyped 
Participating laboratories 
EQAS 
2000 
EQAS 
2001 
EQAS 
2002 
EQAS 
2003 
EQAS 
2004 
EQAS 
2006 
EQAS 
2007 
 
No. % No. % No. % No. % No. % No. % No. % 
8 9 24 34 35 52 53 66 47 41 32 42 32 66 47 
7 9 24 13 14 19 19 29 21 14 11 35 27 29 21 
6 4 11 9 9 12 12 13 9 16 13 19 15 13 9 
5 3 8 9 9 4 4 11 8 16 13 12 9 11 8 
4 3 8 4 4 1 1 7 5 11 9 7 5 7 5 
3 4 11 8 8 4 4 6 4 10 8 5 4 6 4 
2 2 5 3 3 5 5 2 1 10 8 3 2 2 1 
1 2 5 5 5 1 1 6 4 5 4 4 3 6 4 
0 1 3 11 11 1 1 0 0 4 3 3 2 0 0 
In total 37 100 96 100 99 100 127 100 127 100 130 100 140 100 
Number 
of strains 
correctly 
serotyped 
Participating laboratories 
EQAS 
2008 
EQAS 
2009 
EQAS 
2010 
EQAS 
2011 
EQAS 
2012 
EQAS 
2013 
EQAS 
2014 
AVERAGE 
EQAS 
2000 - 2014 
No. % No. % No. % No. % No. % No. % No. % No. % 
8 50 33 76 50 91 61 82 67 68 47 52 41 70 47 57 44 
7 36 24 29 19 16 11 17 14 29 20 29 23 32 21 24 19 
6 11 7 7 5 12 8 10 8 14 10 15 12 17 11 12 10 
5 14 9 13 8 9 6 2 2 9 6 8 6 6 4 9 7 
4 12 8 5 3 6 5 4 3 5 3 7 6 5 3 6 5 
3 9 6 7 5 2 1 4 3 6 4 7 6 7 5 6 5 
2 8 6 5 3 2 1 1 1 10 7 6 5 4 3 5 4 
1 9 6 6 4 7 5 3 2 2 1 2 2 4 3 4 4 
0 2 1 5 3 3 2 0 0 1 1 0 0 4 3 3 2 
In total 151 100 153 100 148 100 123 100 144 100 126 100 149 100 125 100 
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Table 3. Region-based categorization of EQAS participants’ performance of  
Salmonella serotyping 
Region EQAS iteration No. of labs 
No. of strains 
serotyped  
% strains correctly 
serotyped 
Countries participating 
in EQAS 2014 
A
fr
ic
a 
2001 6 37 73.0 
Cameroun, Egypt, Gambia, 
Kenya (2), Madagascar, 
Mauritius, Morroco, Senegal, 
South Africa, Tunisia  
2002 9 62 87.1 
2003 11 70 71.4 
2004 9 51 62.7 
2006 16 95 71.6 
2007 11 73 80.8 
2008 10 71 49.3 
2009 15 94 75.5 
2010 13 83 67.5 
2011 10 57 79.2 
2012 10 65 60.0 
2013 8 51 74.5 
2014 11 63 76.2 
C
en
tr
al
 A
si
a 
&
  
M
id
dl
e 
Ea
st
  
2001 10 60 50.0 
Bahrain, Georgia, India (2), 
Israel, Jordan, Kazakhstan 
2002 5 30 83.3 
2003 5 35 54.3 
2004 5 33 54.5 
2006 5 35 74.3 
2007 5 40 55.0 
2008 5 34 61.8 
2009 5 32 46.9 
2010 5 22 75.9 
2011 3 23 95.8 
2012 4 30 56.7 
2013 5 38 52.6 
2014 7 37 75.7 
C
ar
ib
be
an
 
2001 0 0 0 
Barbados, Cuba, Jamaica 
2002 0 0 0 
2003 3 18 61.1 
2004 2 8 87.5 
2006 3 14 78.6 
2007 2 9 77.8 
2008 3 14 78.6 
2009 3 12 83.3 
2010 2 13 92.9 
2011 1 7 87.5 
2012 2 16 62.5 
2013 1 5 100.0 
2014 3 15 60.0 
Eu
ro
pe
 
2001 43 323 80.5 
Albania, Belgium, Bulgaria, 
Croatia (2), Cyprus, Czech 
Republic (2), Denmark (2), 
France, Germany (2), Greece (3), 
Hungary, Ireland, Italy (18), 
Kosova, Luxembourg (2), Malta, 
Poland (3), Portugal, Serbia (2), 
Slovak Republic, Slovenia, 
Spain, Sweden, Turkey, United 
Kingdom 
 
2002 50 384 90.0 
2003 60 401 84.8 
2004 57 392 84.7 
2006 52 403 86.4 
2007 54 415 89.4 
2008 50 379 82.3 
2009 47 362 93.1 
2010 45 332 94.1 
2011 42 314 94.6 
2012 47 368 92.9 
2013 42 309 94.5 
2014 52 391 96.2 
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Table 3 (continued). Region-based categorization of EQAS participants’ performance of  
Salmonella serotyping 
Region EQAS iteration No. of labs 
No. of strains 
serotyped  
% strains correctly 
serotyped 
Countries participating 
 in EQAS 2014 
N
or
th
 A
m
er
ic
a 
 
2001 4 32 87.5 
Canada (10), USA (3) 
2002 2 16 100.0 
2003 6 41 95.1 
2004 8 55 81.8 
2006 10 80 96.3 
2007 12 94 97.9 
2008 11 84 95.2 
2009 12 90 92.2 
2010 13 103 100.0 
2011 11 81 97.6 
2012 14 101 93.1 
2013 13 92 97.8 
2014 13 84 100.0 
O
ce
an
ia
  
2001 4 30 100.0 
Australia (3), New Zealand 
2002 6 43 93.0 
2003 6 46 93.5 
2004 5 38 97.4 
2006 5 37 94.6 
2007 4 32 100.0 
2008 4 30 93.3 
2009 4 32 96.9 
2010 4 32 100.0 
2011 4 32 100.0 
2012 4 32 100.0 
2013 4 31 100.0 
2014 4 32 100.0 
R
us
sia
 
2001 1 8 12.5 
Russia (4) 
2002 1 8 62.5 
2003 1 7 14.3 
2004 4 26 69.2 
2006 5 40 80.0 
2007 8 51 80.4 
2008 6 40 90.0 
2009 7 49 91.8 
2010 8 54 87.1 
2011 7 48 87.3 
2012 6 48 87.5 
2013 2 16 75.0 
2014 4 30 93.3 
L
at
in
 A
m
er
ic
a 
 
2001 11 78 57.7 
Argentina, Bolivia, Brazil (2), 
Chile (2), Colombia (3), Costa 
Rica (2), Honduras, Mexico (3), 
Nicaragua, Panama (2), 
Paraguay, Peru, Uruguay (2), 
Venezuela (2) 
 
2002 11 82 87.8 
2003 13 83 75.9 
2004 15 88 79.5 
2006 13 84 84.5 
2007 15 107 88.8 
2008 17 120 71.7 
2009 21 150 77.3 
2010 22 132 80.0 
2011 23 144 83.7 
2012 25 182 73.1 
2013 22 154 83.1 
2014 24 166 84.9 
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Table 3 (continued). Region-based categorization of EQAS participants’ performance of  
Salmonella serotyping 
 
 
 Region 
EQAS 
iteration No. of labs 
No. of strains 
serotyped  
% strains correctly 
serotyped 
Countries participating 
 in EQAS 2014 
So
ut
he
as
t A
si
a 
 
2001 15 113 54.0 
Brunei Darussalam, Cambodia, 
Japan (2), LAO PDR, Malaysia 
(4), Philippines, Rep of Korea 
(2), Singapore, Sri Lanka, 
Taiwan, Thailand (6), Viet Nam 
2002 12 90 92.2 
2003 15 100 81.0 
2004 17 130 81.5 
2006 15 117 84.6 
2007 19 140 91.4 
2008 18 125 81.6 
2009 23 180 81.1 
2010 24 172 90.5 
2011 23 180 98.4 
2012 28 207 77.8 
2013 22 163 89.6 
2014 22 166 94.6 
C
hi
na
  
2001 4 32 96.9 
China (9) 
2002 3 24 100.0 
2003 8 60 75.0 
2004 7 46 78.3 
2006 6 48 85.4 
2007 10 80 91.3 
2008 15 108 94.4 
2009 16 126 95.2 
2010 10 74 92.5 
2012 10 78 80.8 
2013 7 54 92.6 
2014 9 71 93.0 
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Table 4. Salmonella serogroups (SG), serotypes (ST) and deviations (D), WHO EQAS 2014 
 
 
*number of participants reporting the specified deviating result 
 
  
Strain 
ID Correct serotype 
No. of labs 
reporting 
SG 
% DSG 
No. of labs 
reporting 
ST 
% DST Deviating results (*) 
WHO 
S-14.1 
Orion / Orion 
var. 15 I 3,15:y:1,5 153 4.6 137 10.2 
Amager, Amounderness, Elisabethville, Florian, Fufu, Gatineau(3), 
Gbadago, II 3,10:z:1,5, Lexington var. 15+, Meleagridis, Paratyphi 
A, Stockholm 
WHO 
S-14.2 
Hadar / 
Istanbul I 8:z10:e,n,x 158 3.8 137 6.6 
Chomedy, Haifa, Mapo, Molade, Newport, Paratyphi C, Santiago, 
Virginia, Zerifin 
WHO 
S-14.3 IIIa 48:g,z51:- IIIa 48:g,z51:- 106 10.4 90 7.8 
Choleraesuis, Enteritidis, Fitzroy 48:e,h:1,5, II 48:g,m,t:-, IIIb 48:i:z, 
IV 48:g,z51:-, IV 6,7:z36:- 
WHO 
S-14.4 Napoli I 9,12:l,z13:e,n,x 155 3.9 133 16.5 
Bournemouth, Claibornei, Dublin, Enteritidis, Fallowfield, II 
.1.,9,12:b:e,n,x, II .1.,9,12:l,w:e,n,x, Itami, Javiana(2), Kapemba, 
Mahina, Miyazaki, Nordrhein, Zaiman(8) 
WHO 
S-14.5 Ohio I 6,7:b:l,w 157 1.9 133 14.3 
Bonariensis, Colorado(2), Coromandel, Edinburg, Gabon(2), II 
6,7:l,z28:1,5:[z42], Infantis(4), Isangi, Jerusalem, Langeveld(4), 
Montevideo 
WHO 
S-14.6 Enteritidis I 9,12:g,m:- 156 0.6 145 2.1 Antarctica, Macclesfield, Panama 
WHO 
S-14.7 Typhimurium I 4,12:i:1,2 160 1.3 141 4.3 Agama, Farsta, Gloucester(2), Lagos, Tripoli 
WHO 
S-14.8 Kentucky I 8:i:z6 157 4.5 139 4.3 Agama, Hadar, Newport, Paratyphi A, Stuttgart, Warnow 
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Table 5. EQAS participating laboratories’ performance of internal quality control strain  
(WHO S-14.6, Salmonella Enteritidis) serotyping  
 
EQAS 
iteration 
Labs serotyping  
S. Enteritidis correctly 
No. % 
2000 34 92 
2001 64 84 
2004 113 95 
2006 116 94 
2007 135 96 
2008 139 96 
2009 141 93 
2010 138 97 
2011 128 98 
2012 139 96 
2013 130 96 
2014 145 98 
Average 119 95 
 
 
 
Table 6. EQAS participating laboratories’ performance of antimicrobial susceptibility testing of Salmonella strains 
 
EQAS 
iteration 
No. of EQAS 
participating 
laboratories  
% correct test 
results 
 
% minor deviations 
(S ↔ I or I ↔ R)^  
% major 
deviations 
(S → R)^ 
% very major 
deviations  
(R→ S)^ 
% critical deviations 
(R→ S & S → R)^ 
% total deviations 
(S → R & R → S & S ↔ 
I or I ↔ R)^ 
2000 44 92 4 4 0 4 8 
2001 108 91 6 2 1 3 9 
2002 119 92 6 2 1 3 9 
2003* 147 93 4 3 0 3 7 
2004 152 93 4 2 1 3 7 
2006 143 88 8 3 1 4 12 
2007 143 93 4 2 1 3 7 
2008 168 91 4 2 3 5 9 
2009 153 94 3 2 1 3 6 
2010 152 92 4 3 2 5 8 
2011 127 91 4 2 3 5 9 
2012 159 94 3 2 1 3 6 
2013 145 95 3 2 0 2 5 
2014 155 95 3 1 1 2 5 
Average* 137 93 4 2 1 3 8 
*Data do not include one strain which may have lost resistance due to transport or storage stress 
^S, susceptible; I, intermediate; R, resistant 
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Table 7. Antimicrobial susceptibility test results (number of R/I/S) for the EQAS 2014 Salmonella strains* 
 
 
^For antimicrobial abbreviations: see List of Abbreviations page 1 
*In bold: expected interpretation. Grey cell: <90% of laboratories did correct interpretation. R, resistant/I, intermediate/ S, susceptible. 
 
 
 
 
 
 
 
 
 
 
 
Strain Antimicrobial^ 
AMP CTX CAZ CRO CHL CIP GEN NAL SMX TET SXT TMP 
WHO 
S-14.1 5/1/141 2/1/125 3/2/121 0/1/101 1/0/133 1/12/132 2/2/139 1/1/132 4/1/64 3/2/133 2/1/127 0/0/69 
WHO 
S-14.2 4/0/144 3/1/123 1/1/124 1/2/99 2/1/131 21/80/44 3/2/139 133/0/3 8/0/63 133/3/4 3/0/128 0/0/67 
WHO 
S-14.3 4/0/143 0/0/126 0/0/126 0/0/101 0/0/133 0/4/140 5/0/138 2/0/133 1/0/70 3/1/136 0/1/128 0/0/67 
WHO 
S-14.4 144/0/3 2/1/124 3/2/119 0/0/103 0/0/135 3/9/134 2/2/140 2/2/131 69/0/0 135/1/4 122/0/8 64/0/2 
WHO 
S-14.5 2/2/142 0/0/126 3/0/122 0/0/102 0/2/132 0/10/135 3/1/140 3/1/130 5/2/62 3/6/129 2/0/128 0/0/66 
WHO 
S-14.6 10/10/127 5/5/117 8/0/117 1/0/101 0/7/128 0/13/131 134/4/6 1/3/132 60/0/9 7/11/120 2/0/127 0/0/66 
WHO 
S-14.7 145/0/2 119/1/6 114/6/5 100/0/5 129/3/1 46/69/30 136/3/3 132/0/1 73/0/0 135/0/1 128/0/1 68/0/2 
WHO 
S-14.8 144/0/3 5/1/121 7/2/117 4/1/95 3/0/131 137/4/6 120/11/12 133/0/2 67/0/3 133/1/3 5/1/125 5/0/65 
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Table 8. EQAS participants’ performance of Salmonella strains antimicrobial susceptibility testing categorized by antimicrobial 
 
EQAS 
iteration 
No. of 
labs Performance 
Antimicrobial∞ 
AMC AMP CAZ CHL CIP POD CRO CTX GEN KAN NAL SMX STR SXT TET TMP XNL OVERALL 
2000 44 
No. of tests - 343 - 343 334 -     343 312 328 248 312 - 335 295 - 3,193 
% critical deviations* - 6 - 4 1 -     4 4 1 3 4 - 6 1 - 3 
% total deviations^ - 8 - 7 6 -     5 16 4 5 12 - 13 1 - 8 
2001 108 
No. of tests - 822 - 814 813 -     821 623 726 431 679 757 804 416 - 7,706 
% critical deviations*  - 4 - 2 1 -     2 2 2 6 7 2 7 1 - 3 
% total deviations^ - 7 - 3 4 -     4 7 8 9 27 5 18 2 - 9 
2002 119 
No. of tests - 918 - 903 911 -     905 680 885 495 718 724 861 499 - 8,499 
% critical deviations* - 2 - 2 0 -     2 2 2 4 4 7 3 3 - 3 
% total deviations^ - 3 - 3 2 -     16 10 4 4 34 10 7 3 - 9 
2003● 147 
No. of tests - 1,019 - 996 995 -     993 738 947 615 768 929 995 582 - 9,577 
% critical deviations* - 2 - 1 0 -     2 2 1 4 9 2 4 1 - 3 
% total deviations^ - 4 - 2 1 -     2 6 4 5 39 2 11 1 - 7 
2004 152 
No. of tests 973 1,178 - 1,159 1,162 - - 995 1,201 - 1,130 734 947 1051 1,122 729 - 12,381 
% critical deviations* 6 3 - 2 0 - - 0 2 - 1 5 1 3 5 2 - 3 
% total deviations^ 12 5 - 2 1 - - 14 3 - 4 8 21 4 11 2 - 7 
2006 143 
No. of tests 950 1,092 769 1,060 1,110 305 - 956 1,078 - 1,035 649 896 996 1,054 607 225 12,782 
% critical deviations* 9 2 7 3 2 1 - 7 3 - 2 6 5 3 9 1 2 4 
% total deviations^ 22 3 11 15 6 26 - 15 7 - 6 7 22 5 20 2 9 12 
2007 143 
No. of tests 908 1,114 830 1,105 1,101 389 - 914 1,111 - 1,092 678 875 971 1,047 583 258 12,976 
% critical deviations* 6 5 1 0 1 4 - 1 3 - 2 5 4 3 4 1 0 3 
% total deviations^ 17 7 1 6 1 16 - 2 4 - 3 6 26 3 11 2 6 7 
2008 168 
No. of tests - 1,331 961 1,226 1,307 - 791 1,104 1,265 - 1,168 718 867 1,155 1,249 696 - 13,858 
% critical deviations* - 3 3 1 19 - 3 3 4 - 2 4 7 3 6 2 - 5 
% total deviations^ - 8 6 11 21 - 6 6 6 - 4 5 25 4 13 2 - 9 
2009 153 
No. of tests - 1,206 921 1,108 1,190 - 775 1,009 1,143 - 1,095 624 864 1,042 1,114 616 - 12,707 
% critical deviations* - 3 1 1 8 - 0 1 2 - 1 7 9 3 4 1 - 3 
% total deviations^ - 6 1 2 10 - 1 2 3 - 3 9 30 4 10 1 - 6 
2010 152 
No. of tests - 1,173 937 1,118 1,194 - 787 1,026 1,133 - 1,096 566 800 1,012 1,134 604 - 12,580 
% critical deviations* - 4 2 1 3 - 4 4 5 - 1 14 19 4 5 1 - 5 
% total deviations^ - 5 3 2 3 - 8 8 6 - 2 17 55 4 9 1 - 9 
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Table 8 (continued). EQAS participants’ performance of Salmonella strains antimicrobial susceptibility testing categorized by antimicrobial. 
 
∞For antimicrobial abbreviations: see List of Abbreviations page 1 
*R→ S & S → R (R, resistant; S, susceptible) 
^S→R & R→S & S↔I or I↔R (I, intermediate) 
● Data do not include one strain which may have lost resistance due to transport or storage stress 
-, not determined 
EQAS 
iteration 
No. of 
labs Performance 
Antimicrobial∞ 
AMC AMP CAZ CHL CIP POD CRO CTX GEN KAN NAL SMX STR SXT TET TMP XNL OVERALL 
2011 127 
No. of tests - 1099 829 988 1070 - 744 909 999 - 993 542 682 988 1017 493 - 11,353 
% critical deviations* - 5 3 2 20 - 3 4 4 - 7 4 3 3 4 1 - 5 
% total deviations^ - 6 4 2 21 - 3 6 5 - 15 5 42 3 10 2 - 9 
2012 159 
No. of tests - 1228 993 1159 1245 - 834 1058 1161 - 1136 584 814 1054 1163 613 - 13,042 
% critical deviations* - 3 2 1 11 - 2 4 3 - 2 5 2 1 2 1 - 3 
% total deviations^ - 5 2 2 12 - 3 5 4 - 4 7 35 2 5 1 - 7 
2013 145 
No. of tests - 1121 898 1027 1134 - 763 1011 1086 - 1027 491 - 946 1060 545 - 11,109 
% critical deviations* - 2 3 0 2 - 1 3 3 - 2 4 - 2 3 2 - 2 
% total deviations^ - 3 3 1 18 - 2 6 6 - 6 5 - 2 5 2 - 5 
2014 155 
No. of tests - 1176 1003 1072 1161 - 817 1014 1147 - 1078 561 - 1039 1107 541 - 11716 
% critical deviations* - 3 3 1 3 - 1 2 3 - 1 5 - 2 3 2 - 2 
% total deviations^ - 4 4 2 19 - 2 3 5 - 2 6 - 3 5 2 - 5 
Average● 137 
No. of tests 944 1059 905 937 904 347 787 1000 1028 588 909 567 769 974 1004 559 242 10154 
% critical deviations* 7 3 2 1 5 3 2 2 3 3 2 5 6 3 4 1 1 3 
% total deviations^ 17 5 4 3 10 21 4 7 5 10 5 7 31 4 10 2 8 8 
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Table 9. Region-based categorization of EQAS participants’ performance of Salmonella AST 
 
 
 
 
 
 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test 
result 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2014 iteration 
A
fr
ic
a 
2001 7 80.1 9.6 7.7 2.5 10.2 19.8 
Cameroun, Egypt, 
Gambia (2), Ivory 
Coast, Kenya (4), 
Madagascar, Mauritius, 
Morroco, Nigeria (3), 
Senegal, South Africa, 
Sudan, Tunisia, Zambia 
 
2002 10 94.3 4.1 1.0 0.6 1.6 5.7 
2003 13 86.9 6.6 2.8 3.7 6.5 13.1 
2004 11 85.7 7.2 5.2 1.9 7.1 14.3 
2006 20 85.8 7.5 4.1 2.7 6.8 14.3 
2007 16 90.7 4.4 4.0 0.9 4.9 9.3 
2008 19 83.8 6.5 5.5 4.2 9.7 16.2 
2009 22 90.1 4.5 3.6 1.8 5.4 9.9 
2010 22 84.7 6.0 6.5 2.8 9.3 15.3 
2011 17 87.0 5.0 4.7 3.3 8.0 13.0 
2012 18 89.4 5.3 3.5 1.9 5.4 10.6 
2013 16 92.0 3.2 4.0 0.9 4.9 8.0 
2014 20 92.5 3.8 2.0 1.7 3.7 7.5 
C
en
tr
al
 A
sia
 &
 M
id
dl
e 
Ea
st
  
2001 10 87.7 6.3 5.2 0.8 6.0 12.3 
Bahrain, Georgia, India 
(9), Islamic rep. of Iran 
(3), Israel, Jordan, 
Kazakhstan 
2002 6 83.4 9.8 6.6 0.2 6.8 16.6 
2003 8 89.9 4.5 4.0 1.6 5.6 10.1 
2004 10 87.5 6.7 5.5 0.3 5.8 12.5 
2006 7 79.2 10.5 9.8 0.5 10.3 20.8 
2007 8 87.8 5.0 6.2 1.1 7.3 12.2 
2008 12 86.1 6.5 4.0 3.4 7.4 13.9 
2009 6 93.7 4.3 0.9 1.1 2.0 6.3 
2010 7 95.8 2.6 0.2 1.4 1.6 4.2 
2011 4 91.8 4.1 1.8 2.3 4.1 8.2 
2012 8 92.8 4.4 1.6 0.7 2.3 6.6 
2013 8 93.6 5.2 1.0 0.1 1.2 6.4 
2014 17 91.0 4.2 2.9 2.0 4.9 9.0 
C
ar
ib
be
an
  
2001 2 83.5 9.5 7.0 0.0 7.0 16.5 
Barbados, Cuba, 
Dominican Republic, 
Jamaica 
2002 1 95.8 4.2 0.0 0.0 0.0 4.2 
2003 8 91.7 6.4 1.5 0.5 2.0 8.4 
2004 8 94.1 3.1 1.9 0.9 2.8 5.9 
2006 5 92.1 5.4 1.6 1.0 2.6 8.0 
2007 4 95.0 3.1 0.9 0.9 1.8 5.0 
2008 5 90.7 5.5 0.9 2.9 3.8 9.3 
2009 4 93.2 1.8 3.2 1.8 5.0 6.8 
2010 4 90.9 5.4 2.7 0.7 3.4 8.8 
2011 2 96.5 1.4 0.0 2.1 2.1 3.5 
2012 4 91.1 1.5 6.7 0.7 7.4 8.9 
2013 3 90.2 2.6 7.3 0.0 7.3 9.8 
2014 4 78.3 4.7 9.4 7.6 17.0 21.7 
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Table 9 (continued). Region-based categorization of EQAS participants’ performance of Salmonella 
antimicrobial susceptibility testing 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test result 
 
 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2014 iteration 
Eu
ro
pe
 
2001 47 91.3 5.7 2.7 0.3 3.0 8.7 
Albania, Belgium, 
Bulgaria, Croatia (2), 
Cyprus, Denmark (2), 
France, Germany, Greece 
(3), Hungary, Ireland, Italy 
(10), Kosova, Luxembourg 
(2), Malta, Poland (3), 
Portugal, Serbia (2), 
Slovak Republic, Slovenia, 
Spain, Turkey, United 
Kingdom 
2002 57 92.7 5.2 1.2 0.9 2.1 7.3 
2003 64 92.9 3.8 1.0 2.3 3.3 7.1 
2004 58 93.5 4.3 1.4 0.8 2.2 6.5 
2006 54 88.7 7.0 3.8 0.6 4.4 11.3 
2007 49 94.2 3.7 1.6 0.4 2.0 5.7 
2008 51 91.2 4.4 2.5 1.9 4.4 8.8 
2009 40 95.1 2.6 1.3 0.9 2.2 4.8 
2010 39 92.4 4.1 1.2 2.3 3.5 7.6 
2011 36 92.5 4.5 1.7 1.3 3.0 7.5 
2012 40 95.5 2.8 1.2 0.4 1.7 4.5 
2013 37 95.7 2.5 1.4 0.3 1.7 4.2 
2014 40 96.6 2.1 0.8 0.5 1.3 3.4 
N
or
th
 A
m
er
ic
a 
 
2001 4 95.8 3.8 0.0 0.4 0.4 4.2 
Canada (4), USA (4) 
2002 3 90.5 6.9 0.6 2.0 2.6 9.5 
2003 7 93.4 5.2 0.0 1.4 1.4 6.6 
2004 9 94.2 4.2 1.8 0.0 1.8 6.0 
2006 8 94.8 2.9 1.0 1.3 2.3 5.2 
2007 10 95.4 2.9 0.8 0.8 1.6 4.6 
2008 14 96.4 0.6 0.4 2.6 3.0 3.6 
2009 10 98.7 0.0 0.4 0.9 1.3 1.3 
2010 11 94.8 2.6 0.2 2.4 2.6 5.2 
2011 9 92.1 2.6 1.5 3.8 5.3 7.9 
2012 10 96.0 2.1 1.0 0.9 1.9 4.0 
2013 7 98.4 1.3 0.0 0.2 0.2 1.6 
2014 8 96.9 2.2 0.4 0.6 0.9 3.1 
O
ce
an
ia
  
2001 6 91.8 4.7 2.7 0.9 3.6 8.2 
Australia (3), New 
Zealand, Tuvalu 
2002 7 91.7 6.2 0.0 2.0 2.0 8.3 
2003 9 94.3 2.5 1.2 2.0 3.2 5.7 
2004 11 97.1 2.5 0.3 0.1 0.4 2.9 
2006 7 93.4 4.6 0.9 1.1 2.0 6.6 
2007 1 98.9 1.1 0.0 0.0 0.0 1.1 
2008 4 93.9 3.8 0.0 2.3 2.3 6.1 
2009 4 95.9 3.2 0.3 0.6 0.9 4.1 
2010 4 92.5 4.6 0.6 2.3 2.9 7.5 
2011 4 93.8 5.6 0.6 0.0 0.6 6.2 
2012 4 95.5 3.1 0.6 0.9 1.4 4.5 
2013 4 96.8 2.9 0.0 0.3 0.3 3.2 
2014 5 97.4 2.0 0.0 0.6 0.6 2.6 
 
 
 
Appendix 1 – Figure and Tables, page 16 of 37 
 
 
 16
 
Table 9 (continued). Region-based categorization of EQAS participants’ performance of Salmonella antimicrobial 
susceptibility testing. 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test result 
 
 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2014 iteration 
R
us
sia
 
2001 1 81.9 15.3 2.8 0.0 2.8 18.1 
Russia (4) 
2002 1 84.5 9.9 5.6 0.0 5.6 15.5 
2003 1 100.0 0.0 0.0 0.0 0.0 0.0 
2004 4 91.2 6.6 1.5 0.7 2.2 8.8 
2006 5 87.4 8.2 2.7 1.7 4.4 12.6 
2007 8 88.9 5.8 4.8 0.4 5.2 11.0 
2008 6 92.2 4.7 1.4 1.7 3.1 7.8 
2009 6 93.8 2.1 3.3 0.8 4.1 6.2 
2010 8 94.3 3.3 1.3 1.1 2.4 5.7 
2011 7 90.0 4.8 3.2 2.0 5.2 10.0 
2012 6 97.4 2.0 0.0 0.6 0.6 2.6 
2013 2 98.2 1.8 0.0 0.0 0.0 1.8 
2014 4 98.2 0.3 0.9 0.6 1.5 1.8 
L
at
in
 A
m
er
ic
a 
 
 
2001 11 90.8 6.9 1.4 1.0 2.4 9.2 
Argentina, Bolivia, Brazil 
(2), Chile (2), Colombia 
(2), Costa Rica, Ecuador 
(2), El Salvador, 
Guatemala, Honduras, 
Mexico (2), Nicaragua, 
Panama, Paraguay, Peru, 
Suriname, Uruguay (2), 
Venezuela 
2002 13 93.7 4.6 0.7 1.0 1.7 6.3 
2003 12 90.8 4.2 2.0 3.0 5.0 9.2 
2004 17 94.4 4.7 0.8 0.1 0.9 5.6 
2006 16 88.7 6.3 4.5 0.6 5.1 11.3 
2007 17 94.9 1.8 1.9 1.4 3.3 5.0 
2008 20 93.0 3.4 1.5 2.1 3.6 7.0 
2009 20 95.6 2.1 1.1 1.2 2.3 4.4 
2010 23 90.8 2.1 5.6 1.4 7.1 9.2 
2011 22 90.8 2.8 3.1 3.3 6.4 9.2 
2012 25 94.4 1.6 3.0 1.0 4.0 5.6 
2013 25 95.5 2.6 1.2 0.3 1.5 4.2 
2014 24 96.5 1.9 1.1 0.6 1.7 3.5 
C
hi
na
 
 
2001 4 98.9 0.8 0.0 0.3 0.3 1.1 
Brunei Darussalam, 
Cambodia, Japan (2), 
LAO PDR, Malaysia 
(4), Philippines, Rep of 
Korea (2), Sri Lanka 
(2), Taiwan, Thailand 
(8), Viet Nam 
2002 3 96.0 4.0 0.0 0.0 0.0 4.0 
2003 8 90.1 3.6 2.8 3.6 6.4 10.0 
2004 8 96.0 3.2 0.7 0.1 0.8 4.0 
2006 6 89.6 7.0 2.9 0.5 3.4 10.4 
2007 10 98.3 1.1 0.3 0.2 0.5 1.6 
2008 18 92.8 3.7 0.8 2.7 3.5 7.2 
2009 14 94.8 2.2 2.1 0.8 2.9 5.1 
2010 9 92.1 4.5 1.6 1.8 3.4 7.9 
2012 9 95.3 3.0 0.5 1.2 1.6 4.7 
2013 8 96.9 2.0 0.5 0.5 1.0 3.1 
2014 24 95.5 2.9 1.0 0.6 1.6 4.5 
^S. susceptible; I. intermediate; R. resistant 
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Table 9 (continued). Region-based categorization of EQAS participants’ performance of Salmonella antimicrobial 
susceptibility testing.  
 
^S. susceptible; I. intermediate; R. resistant 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test result 
 
 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2014 iteration 
So
ut
he
as
t A
si
a 
 
2001 16 88.1 7.7 2.3 1.9 4.2 11.9 
China (8) 
2002 18 89.0 8.1 1.4 1.6 3.0 11.0 
2003 17 87.4 5.2 4.7 2.7 7.4 12.6 
2004 16 92.8 4.4 2.3 0.5 2.8 7.2 
2006 15 90.0 8.1 1.2 0.8 2.0 10.0 
2007 20 93.9 4.0 1.4 0.7 2.1 6.1 
2008 19 90.5 4.7 2.2 2.6 4.8 9.5 
2009 27 91.8 4.1 3.0 1.2 4.2 8.3 
2010 25 92.8 3.8 1.5 1.9 3.4 7.2 
2011 26 90.5 3.5 2.4 3.5 5.9 9.5 
2012 35 91.7 3.9 3.5 0.9 4.4 8.3 
2013 35 93.4 3.2 2.5 0.7 3.2 6.4 
2014 8 97.0 1.2 0.1 1.6 1.8 3.0 
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Table 10. EQAS participants’ performance of antimicrobial susceptibility testing of quality control strain Escherichia coli ATCC 25922 
 Method 
Perfor-
mance5.6 AMC AMP CAZ CHL CIP POD CRO CTX ENR
2 FFN2 FIS (SMX)3 GEN NAL STR SXT TET TMP XNL
2 
Accepted 
interval1 
MIC (μg/ml)    2-8 2-8 0.06-0.5 2-8 0.004-0.016 
0.25-
1 
0.03-
0.12 
0.03-
0.12 
0.008-
0.03 2-8 8-32 0.25-1 1-4 4-16
4 ≤0.5/9.5 0.5-2 0.5-2 0.25-1 
Disks (mm)   18-24 16-22 25-32 21-27 30-40 23-28 29-35 29-35 32-40 22-28 15-23 19-26 22-28 12-20 23-29 18-25 21-28 26-31 
E
Q
A
S
 
i
t
e
r
a
t
i
o
n
 
(
t
o
t
a
l
 
n
o
.
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
)
 
2000 
(44) MIC & Disk 
No.5 - 37 - 38 35 - - - - - 19 39 37 36 - 42 31 - 
%6 - 27 - 37 20 - - - - - 53 23 35 22 - 42 30 - 
2001 
(107) MIC & Disk 
No.5 - 97 - 97 97 - - - - - 53 99 74 81 90 96 50 - 
%6 - 19 - 20 14 - - - - - 34 12 14 12 14 22 22 - 
2002 
(114) MIC & Disk 
No.5 - 109 - 107 108 - - - - - 57 108 102 82 102 102 66 - 
%6 - 16 - 15 14 - - - - - 26 12 14 11 12 13 11 - 
2003 
(144) MIC & Disk 
No.5 - 140 - 137 138 - - - - - 82 138 132 105 129 137 79 - 
%6 - 14 - 22 9 - - - - - 17 9 16 9 14 19 14 - 
2004 
(140) MIC & Disk 
No.5 117 132 - 128 132 - - 111 - - 84 134 126 110 120 129 87 - 
%6 13 10 - 13 8 - - 18 - - 16 10 9 6 11 13 9 - 
2006 
(137) MIC & Disk 
No.5 116 133 96 126 127 39 - 115 19 - 74 131 122 106 122 125 74 32 
%6 9 14 15 18 8 12 - 21 63 - 29 14 20 11 19 12 17 22 
2007 
(126) MIC & Disk 
No.5 102 124 92 123 121 47 - 104 - 13 64 124 120 97 107 117 67 35 
%6 8 11 9 14 12 9 - 16 - 0 22 6 7 6 13 7 10 11 
2008 
(147) 
MIC & Disk 
No.5 - 147 111 135 144 - - 124 - - 71 145 136 101 129 139 79 - 
%6 - 12 9 10 8 - - 14 - - 14 8 8 12 13 7 13 - 
MIC 
No.5 - 33 23 24 33 - - 23 - - 18 31 23 19 22 28 16 - 
%6 - 0 5 0 6 - - 9 - - 11 0 0 11 9 0 13 - 
Disk 
No.5 - 114 89 112 111 - - 101 - - 53 114 113 82 107 111 63 - 
%6 - 16 10 12 8 - - 15 - - 15 11 10 12 14 9 13 - 
2009 
(129) 
MIC & Disk 
No.5 - 128 100 121 124 - 88 107 - - 63 123 117 98 113 122 70 - 
%6 - 16 13 15 7 - 16 10 - - 11 18 13 10 14 14 11 - 
MIC (27) 
No.5 - 27 19 24 26 - 20 20 - - 14 25 24 19 21 27 25 - 
%6 - 11 11 8 8 - 15 15 - - 21 12 8 5 19 11 13 - 
Disk (102) 
No.5 - 101 81 97 98 - 68 87 - - 49 98 93 79 92 95 55 - 
%6 - 16 14 16 6 - 16 9 - - 10 18 14 11 12 15 11 - 
2010 
(116) 
MIC & Disk No.
5 - 114 97 108 115 - 79 100 - - 51 112 104 84 101 110 63 - 
%6 - 11 9 9 6 - 10 14 - - 11 11 5 5 12 5 15 - 
MIC (25) No.
5 - 25 15 21 25 - 15 17 - - 12 24 19 17 17 24 11 - 
%6 - 12 20 10 8 - 7 18 - - 8 13 16 18 18 17 36 - 
Disk (91) No.
5 - 89 82 87 90 - 64 83 - - 39 88 85 67 84 86 52 - 
%6 - 9 6 8 4 - 9 11 - - 10 9 2 1 10 1 8 - 
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Table 10 (continued). EQAS participants’ performance of antimicrobial susceptibility testing of quality control strain Escherichia coli ATCC 25922 
 Method 
Perfor-
mance5.6 AMC AMP CAZ CHL CIP POD CRO CTX ENR
2 FFN2 FIS (SMX)3 GEN NAL STR SXT TET TMP XNL
2 
Accepted 
interval1 
MIC (μg/ml)    2-8 2-8 0.06-0.5 2-8 0.004-0.016 
0.25-
1 
0.03-
0.12 
0.03-
0.12 
0.008-
0.03 2-8 8-32 0.25-1 1-4 4-16
4 ≤0.5/9.5 0.5-2 0.5-2 0.25-1 
Disks (mm)   18-24 16-22 25-32 21-27 30-40 23-28 29-35 29-35 32-40 22-28 15-23 19-26 22-28 12-20 23-29 18-25 21-28 26-31 
E
Q
A
S
 
i
t
e
r
a
t
i
o
n
 
(
t
o
t
a
l
 
n
o
.
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
)
 
2011 
(112) 
MIC & Disk No.
5 - 111 89 102 109 - 76 96 - - 50 103 103 72 99 107 51 - 
%6 - 17 4 11 7 - 7 9 - - 8 11 8 4 16 7 14 - 
MIC (23) No.
5 - 23 15 18 22 - 16 15 - - 13 22 19 17 16 21 11 - 
%6 - 4 7 0 9 - 6 0 - - 8 9 0 6 6 5 0 - 
Disk (89) No.
5 - 88 74 84 87 - 60 81 - - 37 81 84 55 83 86 40 - 
%6 - 20 4 13 7 - 7 11 - - 8 11 10 4 18 8 18 - 
2012 
(135) 
MIC & Disk No.
5 - 134 111 121 131 - 90 115 - - 53 127 121 89 112 129 66 - 
%6 - 13 12 7 6 - 11 10 - - 11 9 9 8 13 10 21 - 
MIC (37) No.
5 - 37 26 31 35 - 23 28 - - 19 35 31 26 23 35 22 - 
%6 - 3 4 0 3 - 0 4 - - 5 3 3 8 0 0 9 - 
Disk (98) No.
5 - 97 85 90 96 - 67 87 - - 34 92 90 63 89 94 44 - 
%6 - 16 14 9 7 - 15 11 - - 15 11 11 8 16 14 27 - 
2013 
(122) 
MIC & Disk No.
5 - 117 100 112 119 - 82 107 - - 44 113 113 - 101 114 59 - 
%6 - 12 7 5 7 - 4 8 - - 10 6 11 - 8 8 11 - 
MIC (33) No.
5 - 31 25 28 32 - 19 27 - - 17 32 28 - 22 32 22 - 
%6 - 6 4 4 13 - 5 11 - - 18 9 11 - 5 6 5 - 
Disk (89) No.
5 - 86 75 84 87 - 63 80 - - 27 81 85 - 79 82 37 - 
%6 - 13 8 6 5 - 5 6 - - 7 4 9 - 10 7 8 - 
2014 
(115) 
MIC & Disk No.
5 - 111 99 101 108 - 75 97 - - 49 111 103 - 102 104 50 - 
%6 - 5 7 7 6 - 7 14 - - 14 8 8 - 8 7 2 - 
MIC (28) No.
5 - 27 21 24 27 - 16 22 - - 16 28 24 - 21 25 12 - 
%6 - 4 5 4 15 - 6 14 - - 0 14 8 - 14 0 0 - 
Disk (87) No.
5 - 84 78 77 81 - 59 75 - - 33 83 79 - 81 79 38 - 
%6 - 6 8 8 4 - 7 15 - - 21 6 8 - 6 9 3 - 
0For antimicrobial abbreviations: see List of Abbreviations page 1 
1CLSI standard. Performance Standards for Antimicrobial Disk and Dilution Susceptibility testing. 22nd Informational supplement. CLSI document M100-S22. 2012 Wayne. PA. USA 
2CLSI standard. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for bacteria Isolated from Animals. M31-A3. 3rd Edition [Approved Standard]. 2008. Wayne. 
PA. USA 
3FIS (sulfisoxazole) covers the group of SMX (sulfonamides) 
4Quality control range developed by the manufacturer of Sensititre 
5No.. number of laboratories performing the analysis 
6%. percentage of laboratories reporting erroneous results 
-. not determined 
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Table 11. Shigella serotypes (ST) and deviations (D). WHO EQAS 2014 
*number of participants reporting deviating result  
. 
 
 
 
 
 
 
 
 
 
Strain Correct serotype 
 
No. of labs 
reporting 
correct 
identification 
D (%) Deviating 
results  
No. of labs 
reporting 
correct ST 
D (%) Deviating 
results (*) 
WHO 2014 
SH-14.1 S. sonnei N/A 120 3,2 4 NA NA NA 
WHO 2014 
SH-14.2 S. sonnei N/A 116 4,1 5 NA NA NA 
WHO 2014 
SH-14.3 S. flexneri 2 / 2b 122 2,4 3 67 16,3 
2a(9), 
var. X(4) 
WHO 2014 
SH-14.4 S. boydii 2 117 5,6 7 64 7,2 
1(2), 3, 
5, 11 
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Table 12. Region-based categorization of laboratories performing Shigella serotyping in 2014 
Region Year No. of 
laboratories 
No. of strains 
serotyped 
Strains serotyped 
correctly (%) 
Countries participating in the 2014 iteration 
Africa 
2009 8 18 72.2 
Egypt, Ivory Coast, Kenya, Mauritius, South Africa, Tunisia,  
2010 7 16 62.5 
2011 4 10 100.0 
2012 5 18 90.0 
2013 5 8 62.5 
2014 6 12 58.3 
Central Asia & 
Middle East  
2009 3 5 100.0 
Bahrain, India (2), Iran (Islamic rep. of), Israel, Jordan 
2010 3 6 83.3 
2011 2 6 100.0 
2012 3 9 81.8 
2013 4 8 100.0 
2014 8 20 85.0 
China 
2009 13 35 100.0 
China (9) 
2010 9 23 91.3 
2011 - - - 
2012 8 29 90.6 
2013 6 11 100.0 
2014 9 33 93.9 
Caribbean 
2009 - - - 
Barbados, Jamaica 
2010 - - - 
2011 - - - 
2012 1 1 33.3 
2013 - - - 
2014 2 3 66.7 
Europe  
2009 15 40 92.5 
Albania, Belgium, Bulgaria, Czech Republic, Denmark, Germany (2), Greece, 
Ireland, Italy (2), Luxembourg, Malta, Poland, Portugal, Serbia (2), Slovenia 
(2), Spain, Sweden, Turkey, United Kingdom 
2010 15 35 85.7 
2011 16 42 92.9 
2012 19 63 86.3 
2013 18 31 96.8 
2014 23 58 84.5 
North America  
2009 7 18 100.0 
Canada (7), USA 
2010 7 20 100.0 
2011 6 16 100.0 
2012 8 25 80.6 
2013 8 14 100.0 
2014 8 24 95.8 
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Table 12 (continued). Region-based categorization of laboratories performing Shigella serotyping in 2014 
Region Year No. of 
laboratories 
No. of strains 
serotyped 
Strains serotyped 
correctly (%) 
Countries participating in the 2014 iteration 
Oceanic  
2009 3 8 100.0 
Australia (3), New Zealand 
2010 3 8 100.0 
2011 3 8 100.0 
2012 3 12 100.0 
2013 4 10 100.0 
2014 4 13 100.0 
Russia  
2009 6 18 83.3 
Russia (3) 
2010 7 20 75.0 
2011 6 18 88.9 
2012 5 16 80.0 
2013 2 4 100.0 
2014 3 10 100.0 
Latin America  
2009 16 40 97.5 
Argentina, Brazil (2), Chile (2), Colombia, Costa Rica, Ecuador, El Salvador, 
Honduras, Mexico (2), Nicaragua, Panama, Paraguay, Peru, Uruguay, 
Venezuela 
2010 13 33 78.8 
2011 15 37 94.6 
2012 19 58 80.6 
2013 16 30 93.3 
2014 18 54 87.0 
Southeast Asia  
2009 11 30 90.0 
Japan (2), LAO PDR, Malaysia, Philippines, Rep of Korea, Sri Lanka, 
Taiwan, Thailand (4) 
2010 14 32 87.5 
2011 13 33 84.8 
2012 14 47 90.4 
2013 9 17 100.0 
2014 12 30 83.3 
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Table 13. EQAS participating laboratories’ performance of Shigella strains antimicrobial susceptibility testing  
 
EQAS iteration No. of 
participating 
laboratories 
% correct test 
results 
% minor 
deviations 
(S ↔ I or I ↔ R)^ 
% major 
deviations 
(S → R)^ 
% very major 
deviations 
(R → S)^ 
% critical 
deviations 
(S → R & R → S )^ 
% total 
deviations 
(S → R & R → S & 
S ↔ I or I ↔ R)^ 
2008 15 95 2 2 1 3 5 
2009 111 96 2 1 1 2 4 
2010 114 91 2 1 6 7 9 
2011 107 92 2 1 4 5 7 
2012 120 91 3 1 5 6 9 
2013 99 91 6 2 2 4 10 
2014 116 92 4 1 3 4 8 
^S. susceptible; I. intermediate; R. resistant 
 
 
 
 
Table 14. Antimicrobial susceptibility test results (number of R/I/S) for the EQAS 2014 Shigella strains* 
 
Strain Antimicrobial∞ 
AMP CTX CAZ CRO CHL CIP GEN NAL SMX TET SXT TMP 
WHO 
SH-14.1 109/0/1 98/0/0 80/6/12 82/1/1 0/0/96 9/56/46 6/1/100 89/10/1 47/0/0 95/3/2 103/0/2 45/0/2 
WHO 
SH-14.2 106/1/3 94/0/2 68/10/20 77/3/1 1/0/97 0/6/106 95/4/6 4/0/99 46/0/1 96/2/1 100/0/3 47/0/1 
WHO 
SH-14.3 106/1/3 0/1/96 3/0/93 3/0/80 83/7/6 23/52/35 3/0/104 98/0/2 44/0/3 92/2/5 99/0/4 44/1/4 
WHO 
SH-14.4 107/0/4 3/0/95 3/1/94 1/0/82 1/0/95 0/3/105 2/1/102 3/1/98 42/0/5 89/5/6 7/1/94 3/1/41 
∞For antimicrobial abbreviations: see List of Abbreviations page 1 
*In bold: expected interpretation. Grey cell: <90% of laboratories did correct interpretation. R. resistant; I. intermediate; S. susceptible. 
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Table 15. EQAS laboratories’ performance of Shigella strains antimicrobial susceptibility testing categorized by antimicrobial 
 
EQAS 
iteration 
No. of 
labs 
Lab 
performance 
Antimicrobial 
AMP CAZ CHL CIP CTX GEN NAL SMX STR SXT TET TMP CRO OVERALL 
2008 15 
No. of tests 52 44 51 48 48 50 52 7 27 52 52 4 42 529 
% critical deviations* 1 2 1 - 2 1 - - 4 2 4 - 2 1.5 
% total deviations^ 1 2 1 - 2 1 - - 9 2 8 - 2 2.2 
2009 111 
No. of tests 423 358 388 426 372 396 388 211 293 388 386 218 301 4.548 
% critical deviations* 2.4 0.3 2.1 0.2 1.1 2.5 0.5 3.8 5.8 2.3 2.8 1.8 0.3 1.9 
% total deviations^ 3.8 0.3 4.6 0.9 1.1 3.5 1.5 3.8 18.1 3.6 7.5 1.8 0.6 3.8 
2010 114 
No. of tests 424 344 402 434 377 403 382 194 275 363 410 218 291 4.517 
% critical deviations* 1.7 0.6 3.5 40.8 2.4 3.5 2.1 4.6 8.0 8.3 4.4 3.7 0.0 6.4 
% total deviations^ 1.9 1.2 9.2 77.9 3.0 5.5 3.0 6.0 14.6 13.8 5.9 3.8 0.0 11.2 
2011 107 
No. of tests 403 322 353 396 343 359 369 179 246 371 376 178 289 4.184 
% critical deviations* 5.5 5.2 2.2 38.9 2.7 3.3 4.0 1.7 3.6 3.2 2.7 2.2 2.0 5.5 
% total deviations^ 7.7 12.0 4.2 40.7 2.7 4.4 11.0 1.7 10.5 3.2 3.5 2.2 2.0 7.7 
2012 120 
No. of tests 462 376 427 464 400 430 442 196 291 396 426 215 337 4.862 
% critical deviations* 2.6 0.8 5.6 35.3 2.0 4.9 1.6 1.5 9.3 6.3 5.4 1.9 0.9 6.0 
% total deviations^ 3.9 0.8 11.5 38.6 3.8 6.3 3.2 2.0 27.1 8.1 7.5 4.2 2.1 9.2 
2013 99 
No. of tests ‐  351 379 420 384 392 393 164 ‐  346 392 193 309 3723 
% critical deviations* ‐  1.1 2.1 8.3 3.4 2.3 3.3 1.8 ‐  5.8 2.8 3.1 1.0 3.4 
% total deviations^ ‐  0.3 0.6 2.0 0.9 0.6 0.8 1.1 ‐  1.7 0.7 1.6 0.3 9.5 
2014 116 
No. of tests 441 390 386 441 389 424 405 188 ‐  413 398 189 331 4395 
% critical deviations* 2.5 9.7 2.1 7.9 1.3 4.0 2.5 4.8 ‐  3.9 3.5 5.3 2.1 4.1 
% total deviations^ 2.9 14.1 3.9 34.2 1.5 5.4 5.2 4.8 ‐  4.1 6.5 6.3 3.9 8.1 
∞For antimicrobial abbreviations: see List of Abbreviations page 1 
*R→ S & S → R (R. resistant; S. susceptible) 
^S→R & R→S & S↔I or I↔R (I. intermediate) 
-. not determined
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Table 16. Region-based categorization of EQAS participating laboratories’ performance of antimicrobial susceptibility tests for Shigella strains 
 
Region Year No. of 
labs 
 
% correct 
test result 
% minor 
deviations 
(S↔I or I↔R)^ 
% major 
deviations 
(S→R)^ 
% very major 
deviations 
(R→ S)^ 
% critical 
deviations 
(R→ S & S → R)^ 
% total 
deviations 
(S→R & R→S & 
S↔I or I↔R)^ 
Countries participating in the 2014 
iteration 
Africa 
2009 17 93.3 2.4 3.5 0.8 4.3 6.8 
Cameroun, Egypt, Gambia (2), Ivory Coast, 
Kenya (4), Madagascar, Mauritius, Nigeria (2), 
Senegal, South Africa, Sudan, Tunisia, Zambia 
2010 16 84.8 2.5 2.7 10.0 12.7 15.2 
2011 16 86.0 1.8 3.6 8.3 11.9 13.7 
2012 17 82.6 4.2 2.5 10.7 13.2 17.4 
2013 14 87,6 7,2 2,5 2,7 5,2 12,4 
2014 18 85.3 6.1 2.3 6.4 8.7 14.7 
Central Asia 
& Middle 
East  
2009 5 94.8 0.9 3.0 1.3 4.4 5.2 
Bahrain, Georgia, India (9), Islamic rep. of Iran 
(3), Israel, Jordan 
2010 6 90.6 1.2 1.6 6.7 8.3 9.4 
2011 4 92.9 1.6 0.5 4.9 5.4 7.1 
2012 6 92.3 4.0 2.0 1.3 3.4 7.4 
2013 6 86,9 8,5 3,9 0,8 4,6 13,1 
2014 16 85.6 6.7 1.7 6.0 7.7 14.4 
Caribbean  
2009 4 95.6 1.5 0.7 2.2 2.9 4.4 
Barbados, Dominican Republic, Jamaica 
2010 4 88.5 1.5 3.8 6.2 10.0 11.5 
2011 1 97.7 2.3 0.0 0.0 2.3 2.3 
2012 3 84.6 1.9 7.7 5.8 13.5 15.4 
2013 2 87,5 9,4 0,0 3,1 3,1 12,5 
2014 3 76.5 5.1 7.1 11.2 18.4 23.5 
Europe  
2009 22 98.1 1.1 0.7 0.1 0.8 1.9 
Albania, Belgium, Bulgaria, Croatia, Cyprus, 
Denmark, Germany, Greece (2), Ireland, Italy (6), 
Luxembourg, Malta, Poland (2), Serbia (2), 
Slovenia, Spain, Turkey, United Kingdom 
2010 27 93.6 1.5 0.9 3.9 4.8 6.4 
2011 24 94.8 2.2 0.5 2.5 3.0 5.1 
2012 24 96.6 1.7 0.4 1.4 1.7 3.4 
2013 23 93,6 4,8 1,2 0,3 1,5 6,4 
2014 26 96.0 3.2 0.1 0.7 0.8 4.0 
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Table 16 (continued) Region-based categorization of EQAS participating laboratories’ performance of antimicrobial susceptibility tests for Shigella strains 
 
Region Year No. of 
labs 
 
% correct 
test result 
% minor 
deviations 
(S↔I or I↔R)^ 
% major 
deviations 
(S→R)^ 
% very major 
deviations 
(R→ S)^ 
% critical 
deviations 
(R→ S & S → R)^ 
% total 
deviations 
(S→R & R→S & 
S↔I or I↔R)^ 
Countries participating in the 2014 
iteration 
North 
America 
2009 6 100.0 0.0 0.0 0.0 0.0 0.0 
Canada (2), USA 
2010 7 95.0 0.0 0.0 5.0 5.0 5.0 
2011 4 90.1 0.7 3.3 5.9 9.2 9.9 
2012 6 89.5 0.0 2.1 8.4 10.5 10.5 
2013 4 95,2 3,2 0,0 1,6 1,6 4,8 
2014 3 95.4 2.8 0.0 1.9 1.9 4.6 
Oceanic 
2009 - - - - - - - 
Australia, Tuvalu 
2010 1 90.0 10.0 0.0 0.0 0.0 10.0 
2011 1 92.5 5.0 0.0 2.5 2.5 7.5 
2012 1 90.0 7.5 0.0 2.5 2.5 10.0 
2013 1 95,5 4,5 0,0 0,0 0,0 4,5 
2014 2 96.2 3.8 0.0 0.0 0.0 3.8 
Russia 
2009 6 95.5 1.6 1.6 1.3 2.9 4.6 
Russia (3) 
2010 7 92.1 2.9 1.5 3.5 5.0 7.9 
2011 6 94.4 3.6 0.0 2.0 2.0 5.6 
2012 5 96.8 1.4 0.5 1.4 1.8 3.2 
2013 2 95,2 4,8 0,0 0,0 0,0 4,8 
2014 3 98.4 0.8 0.0 0.8 0.8 1.6 
Latin 
America  
2009 20 98.3 1.1 0.4 0.3 0.7 1.7 
Argentina, Bolivia, Brazil (2), Chile (2), 
Colombia, Costa Rica, Ecuador (2), El Salvador, 
Guatemala, Honduras, Mexico (2), Nicaragua, 
Panama, Paraguay, Peru, Suriname, Uruguay (2), 
Venezuela 
2010 22 92.1 1.3 2.1 4.5 6.6 7.9 
2011 20 94.0 1.5 1.3 3.2 4.5 6.0 
2012 24 91.7 1.3 0.6 6.5 7.1 8.3 
2013 23 94.1 3.9 1.2 0.8 2.0 5.9 
2014 23 94.4 3.3 0.5 1.9 2.3 5.6 
^S. susceptible; I. intermediate; R. resistant. 
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Table 16 (continued) Region-based categorization of EQAS participating laboratories’ performance of antimicrobial susceptibility tests for Shigella strains 
 
Region Year No. of 
labs 
 
% correct 
test result 
% minor 
deviations 
(S↔I or I↔R)^ 
% major 
deviations 
(S→R)^ 
% very major 
deviations 
(R→ S)^ 
% critical 
deviations 
(R→ S & S → R)^ 
% total 
deviations 
(S→R & R→S & 
S↔I or I↔R)^ 
Countries participating in the 2014 
iteration 
Southeast 
Asia  
2009 18 94.1 3.9 0.3 1.7 2.0 5.9 
Cambodia, Japan (2), LAO PDR, Malaysia, 
Philippines, Rep of Korea, Sri Lanka, Taiwan, 
Thailand (3), Viet Nam 
2010 16 90.5 2.4 0.7 6.4 7.1 9.5 
2011 19 90.0 2.1 0.8 6.1 6.9 9.0 
2012 27 87.1 5.1 1.9 5.6 7.6 12.7 
2013 19 86,2 7,5 2,9 3,1 6,0 13,5 
2014 13 92.5 4.0 1.1 2.4 3.5 7.5 
China 
2009 12 96.3 2.2 1.0 0.5 1.5 3.7 
China (8) 
2010 8 92.7 1.2 0.6 5.5 6.1 7.3 
2011 - - - - - - - 
2012 7 90.3 2.9 0.0 6.8 6.8 9.7 
2013 5 92,7 3,4 0,4 3,4 3,9 7,3 
2014 8 94.6 2.2 0.3 3.0 3.2 5.4 
^S. susceptible; I. intermediate; R. resistant. 
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Table 17. Proportion of laboratories that obtained the expected result. Number (n/N) and 
percentages of laboratories which correctly detected and confirmed the ESBL and non ESBL 
producing Salmonella and Shigella strains. 
 
Isolate no. Expected interpretation 
Confirmatory tests 
CAZ/Cl:CAZ CTX/Cl:CTX 
WHO 2014 S-14.1 non ESBL 23/24 (96%) 28/29 (97%) 
WHO 2014 S-14.2 non ESBL 23/24 (96%) 28/29 (97%) 
WHO 2014 S-14.3 non ESBL 24/24 (100%) 28/29 (97%) 
WHO 2014 S-14.4 non ESBL 24/25 (96%) 30/30 (100%) 
WHO 2014 S-14.5 non ESBL 24/24 (100%) 28/29 (97%) 
WHO 2014 S-14.6 non ESBL 23/24 (96%) 29/30 (97%) 
WHO 2014 S-14.7 ESBL-producer 62/70 (89%) 68/78 (87%) 
WHO 2014 S-14.8 non ESBL 23/25 (92%) 29/30 (97%) 
WHO 2014 SH-14.1 ESBL-producer 50/55 (91%) 59/64 (92%) 
WHO 2014 SH-14.2 ESBL-producer 45/51 (88%) 56/61 (92%) 
WHO 2014 SH-14.3 non ESBL 21/21 (100%) 25/26 (96%) 
WHO 2014 SH-14.4 non ESBL 20/22 (91%) 25/27 (93%) 
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Table 18. EQAS participating laboratories’ performance of Campylobacter strains identification 
EQAS 
iteration 
No. of 
labs 
Correct species Strain no. No. of results 
submitted 
% correct 
identification 
Deviating results (*) 
2003 
97 C. jejuni # 1 93 88%  C. coli (9) C. lari (3) 
97 C. coli # 2 93 84%  
C. jejuni (7) 
C. lari (4) 
C. upsaliensis (4) 
2004 
109 C. lari # 1 97 79%  C. coli (11) C. jejuni (8) 
109 C. jejuni # 2 109 87%  
C. coli (8) 
C. lari (4) 
C. upsaliensis (2) 
2006 
99 C. jejuni # 1 87  90% 
C. lari (3) 
C. coli (3) 
C. upsaliensis (3) 
99 C. coli # 2 95  65%  
C. lari (19) 
C. jejuni (11) 
C. upsaliensis (2) 
2007 
142 C. lari # 1 98  74% 
C. jejuni (10) 
C. coli (9) 
C. upsaliensis (7) 
142 C. coli # 2 102  76%  
C. lari (3) 
C. jejuni (20) 
C. upsaliensis (2) 
2008 
154 C. lari # 1 109 62% 
C. coli (14) 
C. jejuni (18) 
C. upsaliensis (7) 
154 C. lari # 2 109 62% 
C. coli (10) 
C. jejuni (19) 
C. upsaliensis (13) 
2009 
131 C. coli # 1 87 77% 
C. upsaliensis (10) 
C. jejuni (9) 
C. lari (1) 
131 C. jejuni # 2 87 95% C. upsaliensis (3) C. lari (1) 
2010 
130 C. jejuni # 1 88 92% 
C. coli (4)  
C. lari (3) 
C. upsaliensis (1) 
130 C. coli # 2 84 85% 
C. jejuni (11)  
C. lari (2)  
C. upsaliensis (2) 
2011 
132 C. coli # 1 81 59% 
C. jejuni (19)  
C. lari (13)  
C. upsaliensis (1) 
132 C. coli # 2 79 70% 
C. jejuni (17)  
C. lari (5)  
C. upsaliensis (2) 
2012 
135 C. jejuni # 1 112 96% C. coli (4) 
135 C. jejuni # 2 103 85% 
C. coli (10)  
C. lari (5)  
C. upsaliensis (1) 
2013 
123 C. coli # 1 95 82% 
C. jejuni (13)  
C. lari (3)  
C. upsaliensis (1) 
123 C. coli # 2 92 84% 
 C. jejuni (9) 
 C. lari (4)  
 C. upsaliensis (2) 
2014 101 C. coli #2 101 85 % 
C. jejuni (8)  
C. lari (6) 
C. upsaliensis (1) 
*number of participants reporting the specified deviating result 
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Table 19. Region-based categorization of EQAS 2014 participating laboratories’ performance of 
Campylobacter strains identification 
Region Year No. of labs 
No. of strains 
identified 
% strains 
correctly 
identified 
Countries participating in the 
2014 iteration 
Africa 
2009 9 15 53 
Cameroun, Kenya (2), Madagascar, 
Mauritius, Nigeria, Senegal, South 
Africa, Tunisia 
2010 7 13 77 
2011 10 19 32 
2012 9 17 82 
2013 9 17 41 
2014 9 9 67 
Central Asia & 
Middle East 
2009 14 27 85 
Bahrain, India (3), Islamic rep. of  
Iran(2), Israel 
2010 13 26 89 
2011 2 4 50 
2012 11 22 96 
2013 1 8 50 
2014 7 7 57 
Caribbean 
2009 2 4 100 
Barbados, Jamaica 
2010 3 6 67 
2011 1 2 0 
2012 4 7 57 
2013 2 4 100 
2014 2 2 100 
Europe 
2009 29 55 89 
Bulgaria, Czech Republic, Denmark (2), 
Germany (2), Greece, Hungary, Italy 
(8), Luxembourg (2), Malta, Poland (2), 
Serbia (2), Slovenia, Spain, Turkey 
2010 29 57 97 
2011 25 48 85 
2012 29 56 95 
2013 26 51 88 
2014 26 26 89 
North America 
2009 10 19 90 
Canada (6), USA (4) 
2010 11 22 86 
2011 9 18 78 
2012 13 26 96 
2013 10 18 100 
2014 10 10 100 
Oceania 
2009 2 4 100 
New Zealand 
2010 2 3 100 
2011 2 4 100 
2012 2 4 100 
2013 2 4 100 
2014 1 1 100 
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Table 19 (continued). Region-based categorization of EQAS 2014 participating laboratories’ 
performance of Campylobacter strains identification 
Region Year No. of labs 
No. of 
strains 
identified 
% strains 
correctly 
identified 
Countries participating in the 
2014 iteration 
Russia 
2009 2 4 100 
Russia (3) 
2010 2 4 100 
2011 2 4 50 
2012 5 10 80 
2013 1 2 100 
2014 3 3 100 
Latin America 
2009 14 26 89 
Argentina, Bolivia, Brazil (2), Chile 
(2), Colombia (3), Costa Rica, 
Ecuador, El Salvador, Guatemala, 
Mexico, Panama, Paraguay, Peru, 
Suriname, Uruguay (2), Venezuela (2) 
2010 19 37 78 
2011 19 37 49 
2012 22 40 95 
2013 20 36 83 
2014 22 22 86 
Southeast Asia 
2009 10 20 90 
Brunei Darussalam, Cambodia, Japan 
(2), LAO PDR, Malaysia, Philippines, 
Rep of Korea (2), Taiwan, Thailand (3) 
2010 14 27 93 
2011 12 24 67 
2012 17 33 85 
2013 15 28 89 
2014 13 13 92 
China 
2009 12 24 92 
China (8) 
2010 10 20 85 
2011 - - - 
2012 - - - 
2013 5 10 90 
2014 8 8 75 
 
 
Table 20. EQAS participants’ performance of Campylobacter strains antimicrobial susceptibility 
testing 
 
EQAS 
iteration 
No. of 
labs  
% correct 
test results 
 
% major 
deviations 
(S → R)^ 
% very major 
deviations 
(R → S)^ 
% critical 
deviations 
(R → S & S → R)^ 
2009 25 91.4 4.5 4.1 8.6 
2010 37 91.3 4.2 4.5 8.7 
2011 38 93.8 2.8 3.4 6.2 
2012 47 93.6 5.0 1.5 6.4 
2013 47 92.4 5.0 2.6 7.6 
2014 50 91.2 1.6 7.2 8.8 
^S. susceptible; R. resistant 
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Table 21. Antimicrobial susceptibility test results (number of R/S) for the EQAS 2014 
Campylobacter strains* 
 
 
 
 
 
 
^For antimicrobial abbreviations. see List of Abbreviations page 1 
*In bold: expected interpretation. Grey cell: <90% of laboratories did correct interpretation.  
R. resistant; S. susceptible 
 
 
 
Table 22. EQAS participants’ performance of Campylobacter antimicrobial susceptibility testing 
categorized by antimicrobial 
 
EQAS 
iteration 
No. of 
labs 
Lab 
performance 
Antimicrobial 
CHL CIP ERY GEN NAL STR TET 
2009 
 
25 
 
No. of tests 37 46 46 43 41 34 45 
% critical deviations* 8.1 6.5 10.9 2.3 9.8 11.8 11.1 
2010 
 
37 
No. of tests 44 70 71 59 53 39 68 
% critical deviations* 4.5 7.1 11.3 10.2 7.5 10.3 8.8 
2011 
 
38 
No. of tests 41 67 62 65 62 30 60 
% critical deviations* 0.0 6.0 6.5 3.1 8.1 13.3 8.3 
2012 
 
47 
No. of tests 70 84 81 81 39 53 74 
% critical deviations* 4.3 6.0 6.2 7.4 5.1 11.3 5.4 
2013 
 
47 
No. of tests 71 90 87 82 79 51 86 
% critical deviations* 5.6 6.7 8.0 0.0 8.9 23.5 8.1 
2014 50 
No. of tests - 49 46 45 42 24 45 
% critical deviations* - 8.2 2.2 6.7 11.9 16.7 11.1 
^For antimicrobial abbreviations. see List of Abbreviations page 1 
*R→ S & S → R (R. resistant; S. susceptible 
 
  
Strain 
Antimicrobial^ 
CIP ERY GEN NAL STR TET 
WHO 2014 C-14.2 45/0/4 1/0/45 3/0/42 37/0/5 20/0/4 40/0/5 
Appendix 1 – Figure and Tables, page 33 of 37 
 
 
 33
Table 23. Region-based categorization of EQAS 2014 participants’ performance of antimicrobial 
susceptibility testing of Campylobacter strains 
 
Region Year No. of 
labs 
% correct 
test result 
% major 
deviations 
(S → R)^ 
% very 
major 
deviations 
(S → R)^ 
% critical 
deviations 
(R→S & 
S→R)^ 
Countries participating 
in the 2014 iteration 
 
 
Africa 
2009 2 75.0 10.7 14.3 25.0 
Cameroun, Kenya (2), 
Madagascar, Nigeria, 
Senegal, Tunisia 
2010 2 95.2 0.0 4.8 4.8 
2011 7 85.0 3.3 11.7 15.0 
2012 4 94.3 0.0 5.7 5.7 
2013 5 90.9 5.5 3.6 9.1 
2014 7 51.5 39.4 9.1 48.5 
Central Asia 
& Middle East 
2009 0 - - - - 
India, Islamic rep. of Iran, 
Israel 
2010 0 - - - - 
2011 1 75.0 0.0 25.0 25.0 
2012 2 93.8 6.3 0.0 6.3 
2013 3 93.3 3.3 3.3 6.7 
2014 3 100.0 0.0 0.0 0.0 
China 
2009 2 95.2 4.8 0.0 4.8 
China (6) 
2010 1 100.0 0.0 0.0 0.0 
2011 0 - - - - 
2012 2 88.5 7.7 3.8 11.5 
2013 3 95.2 2.4 2.4 4.8 
2014 6 100.0 0.0 0.0 0.0 
Caribbean 
2009 0 - - - - 
Cuba, Jamaica 
2010 0 - - - - 
2011 0 - - - - 
2012 1 75.0 25.0 0.0 25.0 
2013 1 100.0 0.0 0.0 0.0 
2014 2 100.0 0.0 0.0 0.0 
Europe 
2009 10 94.8 3.0 2.2 5.2 
Denmark, Germany, 
Greece, Hungary, Italy (3), 
Luxembourg (2), Malta, 
Poland (2), Serbia, 
Slovenia, Spain, Turkey 
2010 13 100.0 0.0 0.0 0.0 
2011 11 100.0 0.0 0.0 0.0 
2012 16 97.3 1.6 1.1 2.7 
2013 16 94.9 3.5 1.5 5.1 
2014 16 97.4 1.3 1.3 2.6 
North 
America 
2009 2 100.0 0.0 0.0 0.0 
Canada, USA (3) 
2010 5 93.8 6.3 0.0 6.3 
2011 5 100.0 0.0 0.0 0.0 
2012 5 100.0 0.0 0.0 0.0 
2013 3 100.0 0.0 0.0 0.0 
2014 4 100.0 0.0 0.0 0.0 
^S. susceptible; R. resistant 
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Table 23 (continued). Region-based categorization of EQAS 2014 participants’ performance of 
antimicrobial susceptibility testing of Campylobacter strains 
 
Region Year No. of 
labs 
% correct 
test result 
% major 
deviations 
(S → R)^ 
% very 
major 
deviations 
(S → R)^ 
% critical 
deviations 
(R→S & 
S→R)^ 
Countries participating 
in the 2014 iteration 
 
 
Oceania 
2009 0 - - - - 
- none - 
2010 0 - - - - 
2011 1 100.0 0.0 0.0 0.0 
2012 0 - - - - 
2013 0 - - - - 
2014 0 - - - - 
Russia 
2009 0 - - - - 
- none - 
2010 1 78.6 7.1 14.3 21.4 
2011 1 100.0 0.0 0.0 0.0 
2012 0 - - - - 
2013 0 - - - - 
2014 0 - - - - 
Latin America 
2009 5 93.2 6.8 0.0 6.8 
Argentina, Brazil, Chile (2), 
Costa Rica, Paraguay 
2010 8 89.6 6.0 4.5 10.4 
2011 7 96.8 0.0 3.2 3.2 
2012 7 95.2 3.2 1.6 4.8 
2013 7 92.4 4.5 3.0 7.6 
2014 6 100.0 0.0 0.0 0.0 
Southeast Asia 
2009 4 84.4 4.4 11.1 15.6 
Philippines, Rep of Korea 
(2), Thailand (3) 
2010 7 77.2 9.8 13.0 22.9 
2011 5 85.1 9.0 6.0 14.0 
2012 10 85.8 13.3 0.9 14.2 
2013 9 84.8 10.7 4.5 15.2 
2014 6 87.5 12.5 0.0 12.5 
^S. susceptible; R. resistant 
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Table 24. EQAS participants’ performance of antimicrobial susceptibility testing of Campylobacter 
jejuni ATCC 33560 
 
Method used Incubation conditions 
Labs’ 
performance1. 2 
Antimicrobial3 
CHL CIP ERY GEN NAL TET 
EQAS 
2010 
(N=20) 
Microdilution 42°C / 24h 
No.1 3 6 6 6 4 6 
%2 67 83 100 83 75 83 
Microdilution 36-37°C / 48h 
No.1 5 8 8 8 7 8 
%2 80 88 88 75 86 88 
Agardilution 42°C / 24h 
No.1 - 6 6 6 - - 
%2 - 100 83 83 - - 
Agardilution 36-37°C / 48h 
No.1 - 0 0 0 - - 
%2 - 0 0 0 - - 
Overall Overall 
No.1 8 20 20 20 11 14 
%2 75 90 90 80 82 86 
EQAS 
2011 
(N=26) 
Microdilution 42°C / 24h 
No.1 4 9 9 8 7 9 
%2 100 67 100 88 100 67 
Microdilution 36-37°C / 48h 
No.1 6 8 6 8 7 7 
%2 83 88 100 75 86 86 
Agardilution 42°C / 24h 
No.1 - 8 8 8 - - 
%2 - 88 63 100 - - 
Agardilution 36-37°C / 48h 
No.1 - 1 1 1 - - 
%2 - 0 0 100 - - 
Overall Overall 
No.1 10 26 24 25 14 16 
%2 90 77 83 88 93 75 
EQAS 
2012 
(N=34) 
Microdilution 42°C / 24h 
No.1 9 12 12 12 10 12 
%2 67 75 83 83 80 75 
Microdilution 36-37°C / 48h 
No.1 7 9 8 8 8 8 
%2 100 89 100 63 88 88 
Agardilution 42°C / 24h 
No.1 - 9 7 9 - - 
%2 - 89 86 89 - - 
Agardilution 36-37°C / 48h 
No.1 - 4 4 4 - - 
%2 - 50 100 100 - - 
Overall Overall 
No.1 34 80 75 78 43 50 
%2 82 81 88 83 86 80 
1No.. number of labs performing the analysis, 2%. percentage of labs reporting correct results, 3For antimicrobial 
abbreviations: see List of Abbreviations page 1, -. not determined 
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Table 24 (continued). EQAS participants’ performance of antimicrobial susceptibility testing of 
Campylobacter jejuni ATCC 33560 
 
Method used Incubation conditions 
Labs’ 
performance1. 2 
Antimicrobial3 
CHL CIP ERY GEN NAL TET 
EQAS 
2013 
(N=47) 
Microdilution 42°C / 24h 
No.1 6 8 8 8 7 8 
%2 83 88 100 88 86 100 
Microdilution 36-37°C / 48h 
No.1 8 12 12 11 11 12 
%2 88 92 83 73 91 75 
Agardilution 42°C / 24h 
No.1 - 9 9 8 - - 
%2 - 89 67 75 - - 
Agardilution 36-37°C / 48h 
No.1 - 7 7 6 - - 
%2 - 86 86 100 - - 
Overall Overall 
No.1 14 36 36 33 18 20 
%2 86 89 83 82 89 85 
EQAS 
2014 
(N=32) 
Microdilution 42°C / 24h 
No.1 - 10 10 10 10 10 
%2 - 90 100 80 100 90 
Microdilution 36-37°C / 48h 
No.1 - 10 10 9 8 10 
%2 - 100 80 89 100 100 
Agardilution 42°C / 24h 
No.1 - 7 7 7 - - 
%2 - 100 71 100 - - 
Agardilution 36-37°C / 48h 
No.1 - 5 5 5 - - 
%2 - 80 80 100 - - 
Overall Overall 
No.1 - 32 32 31 18 20 
%2 - 94 84 90 100 95 
1No.. number of labs performing the analysis, 2%. percentage of labs reporting correct results, 3For antimicrobial 
abbreviations: see List of Abbreviations page 1, -. not determined 
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Table 25. EQAS participating laboratories’ performance of unknown strain identification  
 
 
EQAS 
iteration 
Strain ID No. of 
participating labs 
Percentage (%) of labs performing correct identification  
2003 E. coli O157 115 99 
2004 Shigella flexneri 121 94 (Shigella) 74 (S. flexneri) 
2006 Yersinia enterocolitica O3 134 
93 (Yersinia) 
89 (Y. enterocolitica) 
66 (Y. enterocolitica O3) 
2007 Vibrio parahaemolyticus 86 83  
2008 Enterobacter sakasakii 128 92  
2009 Vibrio mimicus 56 48  
2010 Citrobacter spp. 115 90 
2011 Aeromonas hydrophila 106 83 
2012 Salmonella Paratyphi B  var. Java 134 
23% (Salmonella spp) 
7% (Salmonella O:B) 
24% (Salmonella Paratyphi B var. java. 
In total 54% 
Deviations:  
Citrobacter freundii (1), Edwardsiella sp (1), Escherichia 
fergusonii (1), Proteus mirabilis (1), Salmonella serovar X* 
(24), Salmonella serovar Paratyphi B (34) 
* incorrect serovar 
2013 E. coli O157:H16 non-VTEC 129 
82% including: 
Escherichia coli non-VTEC 
Escherichia coli O157 non-VTEC 
Escherichia coli O157:H16 non-VTEC 
E. coli non-VTEC 
E. coli O157 non-VTEC 
E. coli O157:H16 non-VTEC 
Deviations:  
Escherichia coli O157 H7 (9), Escherichia hermannii (2), 
Shigella sonnei (2), E.coli EHEC, Escherichia coli O114: 
nonmotile, Escherichia coli O157:H12, Escherichia coli 
O157:H16, Stx1+, Escherichia coli O157:H45, Escherichia 
coli O157:H7/ Verotoxin negative, Escherichia fergusonii, 
Esherichia coli STEC, Vibrio mimicus, Citrobacter 
amalonaticus 
2014 Yersinia pseudotuberculosis  122 
74% Correct, including: 
Yersinia pseudotuberculosis 
Yersinia pseudotuberculosis API 20 E [1014100] 
Yersinia pseudotuberculosis I 
yersinia pseudotuberculosis O:1b 
Yersinia pseudotuberculosis O1 
YERSINIA SPECIES 
Deviations: 
Acinetobacter baumannii, bacteria Sphingomonas 
paucimoilis, Burkolderia sp., Citrobacter freundi, 
corynebacterium species, Gram negative sphingomonas 
paucimobilis, HELICOBACTER, Pasteurella maisi, 
Pasteurella sp., Pseudomonas luteola, Rhizobium radiobacter 
(5), Salmonella typhi, Shigella flexineri, Sphingomonas 
paucimobilis (4), unknown, Vibrio metschnikovii, Yersinia 
enterocolitica (4), Yersinia similis, Yestina pestis 
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M00-06-001/01.12.2011 
Kgs. Lyngby, Denmark, April 2014 
 
SIGN-UP FOR EQAS 2014 
Greetings to the WHO Global Foodborne Infections Network (WHO GFN) Members: 
WHO GFN strives to increase the quality of laboratory-based surveillance of Salmonella and other 
foodborne pathogens by encouraging national and regional reference laboratories that attended 
WHO GFN training courses to participate in the External Quality Assurance System (EQAS). The 
2013 EQAS cycle is completed, and we are pleased to announce the launch of the 2014 EQAS 
cycle. 
 
WHY PARTICIPATE IN EQAS? 
EQAS provides the opportunity for proficiency testing which is considered an important tool for the 
production of reliable laboratory results of consistently good quality. 
 
WHAT IS OFFERED IN EQAS? 
This year, WHO EQAS offers the following components:  
- Serogrouping, serotyping and antimicrobial susceptibility testing of eight Salmonella isolates;  
- Serotyping and antimicrobial susceptibility testing of four Shigella isolates;  
- Species identification and antimicrobial susceptibility testing of two Campylobacter isolates;  
- Identification of one unknown bacterial isolate. 
 
WHO SHOULD PARTICIPATE IN EQAS 2014? 
All national and regional reference laboratories which perform analysis on Salmonella, Shigella 
and/or Campylobacter and are interested in participating in an external quality assurance program 
are invited to participate. 
We expect that all national and regional reference laboratories that attended WHO GFN Training 
Courses will participate in EQAS.  
The WHO GFN Regional Centers in cooperation with the EQAS Coordinator will evaluate the list 
of laboratories that sign up for EQAS 2014. Laboratories which signed up and received bacterial 
isolates in year 2013 but did not submit any result should provide a consistent explanation for this if 
they want to participate in 2014.  
 
COST FOR PARTICIPATING IN EQAS 
There is no participation fee in EQAS 2014. Laboratories should, however, cover the expenses for 
parcel shipment if they can afford it. If FedEx has ‘Dangerous Goods-service’ in your country or if 
you have a DHL-account no, please provide your FedEx or DHL import account number (for 
import of UN3373 Biological Substance Category B) in the sign-up form or, alternatively, to the 
EQAS Coordinator (please find contact information below). We need this information at this stage 
to save time and resources. Participating laboratories are responsible for paying any expenses 
related to taxes or custom fees applied by their country.  
 
HOW TO SIGN- UP FOR EQAS 2014 
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This link will open a sign-up webpage: http://eqas.food.dtu.dk/who/signup  
In this webpage, you will be asked to provide the following information: 
-       Name of institute, department, laboratory, and contact person 
-       Complete mailing address for shipment of bacterial isolates (no post-office box number) 
-       Telephone and fax number, e-mail address 
-       FedEx or DHL import account number (if available) 
-       Approximate number of Salmonella isolates annually serogrouped/serotyped 
-       Approximate number of Salmonella isolates annually tested for antimicrobial susceptibility 
-       Availability of ATCC reference strains 
-       Components of EQAS 2014 you plan to participate in 
-       Level of reference function in your country  
 
If you experience any problem in the sign-up webpage, please try again a few days later. If 
problems persist after several attempts, please contact the EQAS Coordinator Susanne Karlsmose: 
E-mail suska@food.dtu.dk; fax +45 3588 6341.  
 
TIMELINE FOR SHIPMENT OF ISOLATES AND AVAILABILITY OF PROTOCOLS 
Due to increased number of participants in WHO EQAS, a number of different institutions will ship 
the bacterial isolates, and you will receive information concerning the institution shipping your 
parcel. The bacterial isolates will be shipped between August and September 2014. 
In order to minimize delays, please send a valid import permit to the EQAS coordinator. Please 
apply for a permit to receive the following (according to your level of participation): “UN3373, 
Biological Substance Category B”: eight Salmonella strains, four Shigella strains, two 
Campylobacter, one Campylobacter reference strain (for new participants performing antimicrobial 
susceptibility testing on Campylobacter), one Escherichia coli reference strain (for new participants 
performing antimicrobial susceptibility testing on Salmonella and/or Shigella) and an unknown 
isolate (enteric bacteria) between August and September 2014. 
 
Protocols and all relevant information will be available for download from the website 
http://www.antimicrobialresistance.dk/233-169-215-eqas.htm. 
 
DEADLINE FOR SUBMITTING RESULTS TO THE NATIONAL FOOD INSTITUTE 
Results must be submitted to the National Food Institute (DTU Food) by 31st December 2014 
through the password-protected website. An evaluation report will be generated upon submission of 
results. Full anonymity is ensured, and only DTU Food and the WHO GFN Regional Centre in your 
region will have access to your results. 
Deadline for sign-up for EQAS 2014 is 30th May 2014 
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WHO 2014 S-14.1 Salmonella Orion / Orion var. 15 I 3,15:y:1,5 <=       1 SUSC <=   0.25 SUSC  <=   0.5 SUSC  <=  0.25 SUSC  <=      8 SUSC  <= 0.015 SUSC  <=    0.5 SUSC  <=     4 SUSC  =       32 SUSC  <=      2 SUSC <=    0.25 SUSC  <=   0.12 SUSC
WHO 2014 S-14.2 Salmonella  Hadar / Istanbul I 8:z10:e,n,x <=       1 SUSC <=   0.25 SUSC  <=   0.5 SUSC  <=  0.25 SUSC  <=      8 SUSC  =    0.5 INTER  <=    0.5 SUSC  >     128 RESIST  =       32 SUSC  =       64 RESIST <=    0.25 SUSC  <=   0.12 SUSC
WHO 2014 S-14.3 Salmonella IIIa 48:g,z51:- IIIa 48:g,z51:- <=       1 SUSC <=   0.25 SUSC  <=   0.5 SUSC  <=  0.25 SUSC  <=      8 SUSC  =    0.03 SUSC  <=    0.5 SUSC  =       8 SUSC  =       16 SUSC  <=      2 SUSC <=    0.25 SUSC  <=   0.12 SUSC
WHO 2014 S-14.4 Salmonella Napoli I 9,12:l,z13:e,n,x  >      64 RESIST <=   0.25 SUSC  <=   0.5 SUSC  <=  0.25 SUSC  <=      8 SUSC  =    0.03 SUSC  <=    0.5 SUSC  <=     4 SUSC  >     1024 RESIST  >       64 RESIST  >      32 RESIST  >        4 RESIST
WHO 2014 S-14.5 Salmonella  Ohio I 6,7:b:l,w <=       1 SUSC <=   0.25 SUSC  <=   0.5 SUSC  <=  0.25 SUSC  <=      8 SUSC  =    0.03 SUSC  <=    0.5 SUSC  <=     4 SUSC  =       64 SUSC  <=      2 SUSC <=    0.25 SUSC  <=   0.12 SUSC
WHO 2014 S-14.6 Salmonella  Enteritidis I 9,12:g,m:-  =        2 SUSC <=   0.25 SUSC  <=   0.5 SUSC  <=  0.25 SUSC  <=      8 SUSC  =    0.03 SUSC  >       32 RESIST  <=     4 SUSC  >     1024 RESIST  <=      2 SUSC <=    0.25 SUSC  <=   0.12 SUSC
WHO 2014 S-14.7 Salmonella  Typhimurium I 4,12:i:1,2  >      64 RESIST  >       4 RESIST  >       8 RESIST  >      64 RESIST  >      128 RESIST  =        1 RESIST  >       32 RESIST  >     128 RESIST  >     1024 RESIST  >       64 RESIST  >      32 RESIST  >        4 RESIST
WHO 2014 S-14.8 Salmonella  Kentucky I 8:i:z6  >      64 RESIST <=   0.25 SUSC  <=   0.5 SUSC  <=  0.25 SUSC  <=      8 SUSC  >        8 RESIST  =       16 RESIST  >     128 RESIST  >     1024 RESIST  =       64 RESIST <=    0.25 SUSC  <=   0.12 SUSC
WHO 2014 SH-14.1 sonnei  >      64 RESIST  >       4 RESIST  =       4 RESIST  =      64 RESIST  <=      8 SUSC  =    0.12 INTER  =       1 SUSC  =      64 RESIST  >     1024 RESIST  =      64 RESIST  >      32 RESIST  >        4 RESIST
WHO 2014 SH-14.2 sonnei  >      64 RESIST  >       4 RESIST  =       2 RESIST  =      64 RESIST  <=      8 SUSC  <=  0.015 SUSC  >       32 RESIST  <=     4 SUSC  >     1024 RESIST  =      64 RESIST  >      32 RESIST  >        4 RESIST
WHO 2014 SH-14.3 flexneri 2b  >      64 RESIST <=   0.25 SUSC  <=   0.5 SUSC  <=  0.25 SUSC  =       32 RESIST  =        1 RESIST  =       1 SUSC  >     128 RESIST  >     1024 RESIST  =      64 RESIST  >      32 RESIST  >        4 RESIST
WHO 2014 SH-14.4 boydii 2  >      64 RESIST <=   0.25 SUSC  <=   0.5 SUSC  <=  0.25 SUSC  <=      8 SUSC  <=  0.015 SUSC  <=    0.5 SUSC  <=     4 SUSC  >     1024 RESIST  =      32 RESIST <=    0.25 SUSC  =    0.25 SUSC
WHO 2014 C-14.1
WHO 2014 C-14.2 C. coli  =        8 RESIST  <=      1 SUSC  <=  0.12 SUSC  =       64 RESIST  >     16 RESIST  >      64 RESIST
WHO B-14.1 Yersinia pseudotuberculosis 
AMP CTX CAZ
Nalidixic acidAmpicillin Cefotaxime Ceftazidime Ceftriaxone Chloramphenicol
CRO CHL
Trim/SulfaTrimethoprim
CIP GEN NAL
ERY GEN NAL
TMP SXT
No strain, this year, with this code (due to problems with the lyophilization)
Sulfonamides Tetracycline
Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
SMX TET
STR TET
Ciprofloxacin
Ciprofloxacin Gentamicin
CIP
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PROTOCOL for 
- serotyping and antimicrobial susceptibility testing of Salmonella  
- serotyping and antimicrobial susceptibility testing of Shigella  
- identification and antimicrobial susceptibility testing of Campylobacter  
- identification of an unknown enteric pathogen  
 
 
1  INTRODUCTION .....................................................................................................................  1 
2  OBJECTIVES  ............................................................................................................................ 2 
3  OUTLINE OF THE EQAS 2014  .............................................................................................. 2 
3.1  Shipping, receipt and storage of strains  ....................................................................... 2 
3.2  Serotyping of Salmonella  ............................................................................................... 3 
3.3  Antimicrobial susceptibility testing of Salmonella, Shigella and Escherichia coli ATCC 
25922  ................................................................................................................................ 3 
3.4  Handling the Campylobacter strains  ............................................................................. 5 
3.5  Identification of Campylobacter  ..................................................................................... 6 
3.6  Antimicrobial susceptibility testing of Campylobacter  ................................................ 6 
3.7  Identification of the unknown environmental bacterium  ........................................... 7 
4  REPORTING OF RESULTS AND EVALUATION  .............................................................. 7 
5  HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE ................................ 8 
 
1 INTRODUCTION 
In 2000, the Global Foodborne Infections Network (formerly known as WHO Global Salm-Surv) 
launched an External Quality Assurance System (EQAS). The EQAS is organized by the National 
Food Institute, Technical University of Denmark (DTU Food), in collaboration with partners and 
Regional Sites in WHO GFN.  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs, it is placed with a competent subcontractor and the National Food Institute is 
responsible for the subcontractor’s work. 
The WHO EQAS 2014 includes  
- serotyping and antimicrobial susceptibility testing of eight Salmonella strains,  
- serotyping and antimicrobial susceptibility testing of four Shigella strains,  
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- antimicrobial susceptibility testing of the Escherichia coli ATCC 25922 (CCM 3954) 
reference strain for quality control,  
- identification and antimicrobial susceptibility testing of one thermophilic Campylobacter 
isolate (note, this year, only one Campylobacter strain is included, due to unfortunate issues 
with the lyophilisation of the strains),  
- antimicrobial susceptibility testing of Campylobacter jejuni ATCC 33560 (CCM 6214) 
reference strain for quality control,  
- identification of one ‘unknown’ bacterial isolate.  
All participants will receive the strains according to the information they reported in the sign-up 
form.   
The above-mentioned reference strains are included in the parcel only for new participants of the 
EQAS who did not receive them previously. The reference strains are original CERTIFIED cultures 
provided free of charge, and should be used for future internal quality control for antimicrobial 
susceptibility testing in your laboratory. The reference strains will not be included in the years to 
come. Therefore, please take proper care of these strains. Handle and maintain them as suggested in 
the manual ‘Subculture and Maintenance of QC Strains’ available on the WHO Collaborating 
Centre website (see www.antimicrobialresistance.dk). 
2 OBJECTIVES 
The main objective of this EQAS is to support laboratories to assess and if necessary improve the 
quality of serotyping and antimicrobial susceptibility testing of enteric human pathogens, especially 
Salmonella. A further objective is to assess and improve the comparability of surveillance data on 
Salmonella serotypes and antimicrobial susceptibility reported by different laboratories. Therefore, 
the laboratory work for this EQAS should be done by using the methods routinely used in your 
laboratory. 
3 OUTLINE OF THE EQAS 2014 
3.1 Shipping, receipt and storage of strains 
In September 2014 around 200 laboratories located worldwide will receive a parcel containing eight 
Salmonella strains, four Shigella strains, one Campylobacter strain and one ‘unknown’ bacterial 
isolate (according to information reported in the sign-up form). An E. coli ATCC 25922 reference 
strain and a C. jejuni ATCC 33560 reference strain will be included for participants who signed up 
to perform antimicrobial susceptibility testing (AST) and did not receive them previously. All 
provided strains belong to UN3373, Biological substance category B. ESBL-producing strains 
could be included in the selected material.  
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 Please confirm receipt of the parcel through the confirmation form enclosed in the shipment.  
The Salmonella and Shigella strains, and the ‘unknown’ bacterial isolate are shipped as agar stab 
cultures whereas the reference strains and the Campylobacter strain are shipped lyophilised. On 
arrival, the agar stab cultures must be subcultured and prepared for storage in your strain collection 
(e.g. in a -80°C freezer). This set of cultures should serve as reference if discrepancies are detected 
during the testing (e.g. they can be used to detect errors such as mis-labelling or contamination). 
Lyophilised strains must be reconstituted, and you can find below a suggested procedure. 
3.2 Serotyping of Salmonella  
The eight Salmonella strains should be serotyped by using the method routinely used in the 
laboratory. If you do not have all the necessary antisera please go as far as you can in the 
identification and report the serogroup, since also serogroup results will be evaluated. Serogroups 
should be reported using terms according to Kauffmann-White-Le Minor (Grimont and Weill, 2007. 
9th ed. Antigenic formulae of the Salmonella serovars. WHO Collaborating Centre for Reference 
and Research on Salmonella). 
Please fill in information concerning the brand of antisera used for typing in the fields available in 
the database for entering results. In addition, we kindly ask you to report which antisera you think 
are required to complete the serotyping, if relevant. 
3.3 Antimicrobial susceptibility testing of Salmonella, Shigella and Escherichia coli ATCC 
25922  
The Salmonella and Shigella strains as well as the E. coli ATCC 25922 reference strain should be 
tested for susceptibility towards as many as possible of the antimicrobials mentioned in the test 
form. Please use the methods routinely used in your laboratory.  
For reconstitution of the E. coli reference strain, please see the document ‘Instructions for opening 
and reviving lyophilised cultures’ on the WHO Collaborating Centre website (see 
www.antimicrobialresistance.dk). 
Testing of gentamicin susceptibility may be valuable for monitoring purposes. Therefore we kindly 
ask you to disregard, for the purpose of this proficiency trial, that the Clinical and Laboratory 
Standards Institute (CLSI) guidelines state that Salmonella and Shigella should not be reported as 
susceptible to aminoglycosides. 
The breakpoints used in this EQAS for interpreting MIC results are in accordance with CLSI values 
(Table 1). Consequently, interpretation of MIC results will lead to categorization of strains into 
three categories: resistant (R), intermediate (I) and susceptible (S). In the evaluation report you 
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receive upon result submission, you can find that obtained interpretations in accordance with the 
expected interpretation will be defined as ‘correct’, whereas deviations from the expected 
interpretation will be defined as ‘minor’ (I  S or I  R), ‘major’ (S interpreted as R) or ‘very 
major’ (R interpreted as S).  
Please report the breakpoints that you routinely use in your laboratory for interpretation of 
antimicrobial susceptibility test results in the fields available in the database (or in the test forms). 
Table 1. Interpretive breakpoint for Salmonella and Shigella antimicrobial susceptibility testing 
Antimicrobials  Reference value, MIC (g/mL) Reference value, Disk diffusion (mm)
Sensitive Intermediate Resistant Resistant Intermediate Sensitive 
Ampicillin, AMP 8 16 32 13 14-16 17
Cefotaxime, CTX* ≤1 - >1 27 - >27 
Ceftazidime, CAZ* ≤1 - >1 22 - >22 
Ceftriaxone, CRO* ≤1 - >1 25 - >25 
Chloramphenicol, CHL 8 16 32 12 13-17 18 
Ciprofloxacin, CIP 0.06** 0.12-0.5** 1** 
20mm 
(5µg)** 
or 
<23mm 
(1µg)*** 
21-30mm  
(5µg)** 
or 
- (1µg)***  
31mm 
(5µg)** 
or 
23mm 
(1µg)*** 
Gentamicin, GEN 4 8 16 12 13-14 15 
Nalidixic acid, NAL 16 - 32 13 14-18 19 
Sulfonamides, SMX 256 - 512 12 13-16 17 
Tetracycline, TET 4 8 16 11 12-14 15 
Trimethoprim, TMP 8 - 16 10 11-15 16 
Trimethoprim + 
sulfamethoxazole, 
TMP+SMX, SXT 
2/38 - 4/76 10 11-15 16 
Reference values used in this EQAS are according to CLSI (M100-S24), with the following exceptions:  
* Reference values are according to CLSI M100-S24 Table 3A. These interpretative criteria are also applied 
for Salmonella and Shigella test strains for interpretation of AST results in this EQAS 
** These breakpoints should also be applied for Shigella test strains for interpretation of AST results in this 
EQAS      
*** The publication by Cavaco LM and Aarestrup FM (J. Clin. Microbiol. 2009. Sep;47(9):2751-8) provides 
the background for these interpretative criteria in the WHO GFN EQAS. These interpretative criteria are also 
applied for Shigella test strains for interpretation of AST results in this EQAS. 
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Concerning ciprofloxacin susceptibility tests, please note that for results obtained in this proficiency 
test, the breakpoints for Salmonella are applied for Shigella also. These breakpoints for 
ciprofloxacin take into consideration mechanisms of resistance due to plasmid-mediated quinolone 
resistance genes (e.g. qnr-genes) and one-point-mutation in the gyrase gene. 
Important notes: beta-lactam resistance 
The following tests for detection of Extended-Spectrum Beta-Lactamase (ESBL) production are 
optional.  
All strains showing reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ) and/or 
ceftriaxone (CRO) could be tested for ESBL production by confirmatory test. Confirmatory test for 
ESBL production requires use of both cefotaxime (CTX) and ceftazidime (CAZ) alone, and in 
combination with a -lactamase inhibitor (clavulanic acid). Synergy is defined either as i) a ≥ 3 
twofold concentration decrease in an MIC for either antimicrobial agent tested in combination with 
clavulanic acid vs. its MIC when tested alone (E-test 3 dilution steps difference; MIC CTX : 
CTX/CL or CAZ : CAZ/CL ratio  8) or ii) a  5 mm increase in a zone diameter for either 
antimicrobial agent tested in combination with clavulanic acid vs. its zone when tested alone (CLSI 
M100 Table 2A; Enterobacteriaceae). The presence of synergy indicates ESBL production. 
Of note, MIC values and relative interpretation of cefotaxime (CTX), ceftazidime (CAZ) and/or 
ceftriaxone (CRO) used for detection of beta-lactamase-producing strains in this EQAS should be 
reported as found. 
3.4 Handling the Campylobacter strains 
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule, and all instructions given below should be followed closely to ensure the safety of the 
person who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule  
b. Make a file cut on the ampoule near the middle of the plug  
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end  
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule  
e. Remove the pointed end of the ampoule into disinfectant  
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media  
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g. Transfer the rest of the content of the ampoule to a test tube containing 5-6 ml of a suitable 
liquid media. 
h. Incubate the agar plate and liquid media at a temperature of 42°C at microaerobic conditions 
for 24-48 hours. 
i. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding  
j. Inoculate a second agar plate from the liquid media with a 10µl loop or a cotton swab if the 
initial plate had inadequate growth. 
k. Select a pure culture with vigorous growth from the agar plate for further work. 
 
Please note that:  
 Cultures may need at least one subculture before they can be optimally used  
 Unopened ampoules should be kept in a dark and cool place! 
For reconstitution of C. jejuni ATCC33560 reference strain, please see the document ‘Instructions 
for opening and reviving lyophilised cultures’ on the WHO Collaborating Centre website (see 
www.antimicrobialresistance.dk). 
3.5 Identification of Campylobacter  
The thermophilic Campylobacter isolate should be identified to species level.  
3.6 Antimicrobial susceptibility testing of Campylobacter 
The Campylobacter test strain and the C. jejuni reference strain ATCC33560 should be tested for 
susceptibility to as many antimicrobials as possible among the ones mentioned in the test form. It 
should be noted that only MIC methods (i.e. broth or agar dilution methods) are recommendable for 
AST of Campylobacter. Neither the use of disk diffusion nor E-test is recommendable for AST of 
Campylobacter.  
In this EQAS, the breakpoints used for interpretation of MIC results for Campylobacter are 
epidemiological cut-off values according to EUCAST (European Committee on Antimicrobial 
Susceptibility Testing; www.eucast.org; Table 2). Consequently, only two categories of 
characterisation (resistant, R or susceptible, S) are allowed. In the evaluation report that you receive 
upon result submission, you can find that obtained interpretations in agreement with the expected 
interpretation, will be categorised as ‘correct’, whereas deviations from the expected interpretation 
will be categorizes as ‘incorrect’.  
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Please report the breakpoints that you routinely use in your laboratory for interpretation of 
antimicrobial susceptibility test results, in the fields available in the database (or in the test form).  
Note that the interpretation of antimicrobial susceptibility test results for Campylobacter requires 
knowledge of the Campylobacter species. If you did not sign-up for Campylobacter identification, 
but perform AST on Campylobacter, you are welcome to contact the EQAS Coordinator to obtain 
information regarding the identity of the Campylobacter test strain. 
 
Table 2. Interpretive criteria for Campylobacter antimicrobial susceptibility testing 
Antimicrobials for Campylobacter MIC (g/mL) R is > 
MIC (g/mL) 
R is > 
 C. jejuni C. coli 
Ciprofloxacin, CIP 0.5 0.5 
Erythromycin, ERY 4 8 
Gentamicin, GEN 2 2 
Nalidixic acid, NAL 16 16 
Streptomycin, STR 4 4 
Tetracycline, TET 1 2 
Reference values for interpretation of Campylobacter AST results according to EUCAST 
 
The sub-cultured Campylobacter strains should be used for MIC-testing after incubation at 36-37ºC 
for 48 hours or at 42ºC for 24 hours. Likely, two subcultures are needed prior to MIC-testing to 
ensure optimal growth.  
3.7 Identification of the unknown environmental bacterium 
The ‘unknown’ isolate should be identified to species level and further typed if relevant.  
4 REPORTING OF RESULTS AND EVALUATION 
We recommend that you write your results in the enclosed test forms and that you read carefully the 
description in paragraph 5 before entering your results in the web database. For entering your 
results via the web, you will be guided through all steps on the screen and you will immediately be 
able to view and print a report evaluating your results. Results in agreement with the expected 
interpretation are categorised as ‘correct’, while results deviating from the expected interpretation 
are categorised as ‘incorrect’. 
Results must be submitted no later than 31 December 2014. 
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If you do not have access to the Internet, or if you experience difficulties in entering your results, 
please return the completed test forms by e-mail, fax or mail to the National Food Institute, 
Denmark. 
 
All results will be summarized in a report which will be publicly available. Individual results will 
be anonymous and will only be forwarded to the official GFN Regional Centre in your region. 
We are looking forward to receiving your results.  
If you have any questions or concerns, please do not hesitate to contact the EQAS 
Coordinator: 
Susanne Karlsmose 
National Food Institute, Technical University of Denmark 
Kemitorvet, Building 204 ground floor, DK-2800 Lyngby - DENMARK 
Tel: +45 3588 6601, Fax: +45 3588 6341 
E-mail: suska@food.dtu.dk 
It is possible to communicate with the EQAS organisers in other languages than English. However, 
this is not a direct contact with the EQAS organisers since translation of the message is required. 
The following languages may be used: Chinese, French, Portuguese, Russian and Spanish. 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please carefully read these instructions before entering the web page. Remember that you need by 
your side the completed test forms and the breakpoint values you used.  
In general, you can browse back and forth in the pages of the database. Always remember to save 
your input before leaving a page. 
1) Enter the WHO Collaborating Centre website (from http://www.antimicrobialresistance.dk), then 
a. Click on ‘EQAS’ 
b. Click on the link for the interactive database (http://eqas.food.dtu.dk/who) 
c. Write your username and password in lower-case letters and click on ‘Login’. 
You can find your username and password in the letter following your strains.  
Your username and password will remain unchanged in future trials. Do not hesitate to 
contact us if you experience problems with the login. 
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2) Click on ‘Materials and methods’  
a. Fill in the fields relative to brand of antisera (very important because we would like to 
compare results obtained with different brands of antisera) 
b. Fill in the fields relative to the method used for antimicrobial susceptibility testing 
c. Enter the brand of materials, e.g. Oxoid 
d. Fill in the field asking whether your institute serves as a national reference laboratory  
e. In the comment field, report which antisera you think is required to complete your 
serotyping, if relevant 
f. Click on ‘Save and go to next page’ – ALWAYS remember to save each page before 
leaving it! 
3) In the data entry page ‘Routinely used breakpoints’ 
a. Fill in the fields relative to the breakpoints used routinely in your laboratory to determine 
the antimicrobial susceptibility category. Remember to use the operator keys in order to 
show – equal to (=), less than (<), less or equal to(≤), greater than (>) or greater than or 
equal to (≥). 
4) In the data entry pages ‘Salmonella strains 1-8’, 
a. SELECT the serogroup (O-group) from the drop-down list, DO NOT WRITE – Wait a few 
seconds – the page will automatically reload, so that the drop-down list in the field 
“Serotype” only contains serotypes belonging to the chosen serogroup.  
b. SELECT the serotype from the drop-down list – DO NOT WRITE – wait a few seconds 
and you can enter the antigenic formula (e.g. 1,4,5,12:i:1,2)  
c. Enter the zone diameters in mm or MIC values in µg/ml. Remember to use the operator 
keys to show e.g. equal to (=), etc.  
d. Enter the interpretation as R (resistant), I (intermediate) or S (susceptible) 
e. If you performed confirmatory tests for ESBL production, select the appropriate result. 
f. If relevant, fill in the field related to comments (e.g. which antisera you miss for complete 
serotyping)  
g. Click on ‘Save and go to next page’ 
If you did not perform these tests, please leave the fields empty  
5) In the data entry page ‘E. coli reference strain’: 
a. Enter the zone diameters in mm or MIC values in µg/ml. Remember to use the operator 
keys to show e.g. equal to (=), etc. 
b. Click on ‘Save and go to next page’ 
6) In the page ‘Identification of Campylobacter and unknown sample’:  
a. Choose the correct Campylobacter species from the pick list 
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b. Fill in the field concerning species and type of the unknown bacterial isolate, and report the 
method used for identification 
c. Click on ‘Save and go to next page’ 
If you did not perform these tests, please leave the fields empty 
7) The next page is a menu that allows you to review the input pages and approve your input and 
finally see and print the evaluated results 
a. Browse through the input pages and make corrections if necessary. Remember to click on 
‘save and go to next page’ if you make any corrections. 
b. Approve your input. Be sure that you have filled in all the results before approval, as .YOU 
CAN ONLY APPROVE ONCE!. The approval blocks your data entry into the interactive 
database, but allows you to see the evaluated results. 
c. As soon as you have approved your input, an evaluation report will appear.  
8) After browsing all pages in the report, you will find a new menu. You can choose ‘EQAS 20xx 
start page’, ‘Review evaluated results’ (a printer friendly version of the evaluation report is also 
available) or ‘Go to WHO GFN homepage’.   
End of entering your data – thank you very much! 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S21, January 2011 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A8, January 2009 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination.
 Obtain QC strains from a reliable source such as ATCC
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC
validation)
 Any changes in materials or procedure must be validated with QC before implemented
 For example: Agar and broth methods may give different QC ranges for drugs such as
glycopeptides, aminoglycosides and macrolides
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 Periodically perform colony counts to check the inoculum preparation procedure 
 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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DAILY MIC QC CHART 
 
Reference: CLSI M7-A8, page 44 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5a, page 3 of 4
WHO Collaborating Centre  
External Quality Assurance System (EQAS) 
 
 
Subculture and Maintenance of QC strains                                                                              DFVF-M00-06-001/01.09.2011 
 
Page 4 of 4 
 
WEEKLY MIC QC CHART 
 
 
Reference: CLSI M7-A8, page 45 
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
Manual from  Czech Collection of Microorganisms (CCM) 
Masaryk University
Tvrdého 14
602 00 BRNO 
Czech Republic
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule
b. Make a file cut on the ampoule near the middle of the plug
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from
just below the plug to the pointed end
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into
the ampoule
e. Remove the pointed end of the ampoule into disinfectant
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable
solid and /or liquid media
g. Incubate the inoculated medium at appropriate conditions for several days
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of
the original ampoule before discarding
Please note that:  
 Cultures should be grown on media and under conditions as recommended in the CCM
catalogue
 Cultures may need at least one subculturing before they can be optimally used in experiments
 Unopened ampoules should be kept in a dark and cool place!
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